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CHAPTER 1 
INTRODUCTION 
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1.1 miRNAs 
 
The initial perception, that essential cellular processes are regulated by genetic information, 
which is translated into functional proteins, was quite straightforward. This conventional view 
was centered around protein-coding genes, through the common conviction of DNA 
transcribing into mRNA, conclusively translated into proteins. These points of view had to be 
adjusted since the discovery of miRNAs, and we have come to realize that this process is a lot 
more complex than initially perceived. Evidence accumulated from copious amounts of data 
from high-throughput genomic platforms, led to the conclusion that the complexity of any 
organism lies mainly in the expansion of the regulatory potential of the non-coding portions 
of the genome during evolution. These regions were initially perceived as worthless and were 
therefore termed, junk DNA (Mattick, 2004).  
 
1.1.1 The role of noncoding RNAs 
 
It was generally understood that protein encoding genes encompass the majority of 
transcribed data required for proper cell function. This was shown to be incorrect, and we 
have come to realize that the majority of transcribed data are reserved for regulatory non-
protein-coding RNAs (ncRNAs). These ncRNAs are classified by size and function, 
extending from microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), endogenous 
small-interfering RNAs (endo-siRNAs), PIWI interacting RNAs (piRNAs), promoter-
associated RNAs (PARs) and the longer transcribed ultraconserved regions (T-UCRs), and 
long non-coding RNAs (lncRNAs) (Bartel, 2004; Lagos-Quintana et al., 2001; Taft et al., 
2010). See Table 1 for an overview. 
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Table 1. Overview classes of non-coding RNAs in mammals 
 
The diversity of noncoding RNAs with structural, enzymatic and regulatory functions in cells 
is extensive. Currently over 1000 human miRNAs have been discovered, making them one of 
the prominent gene regulators. A repository of miRNAs and miRNA genes from many 
organisms is available at the miRBase Sequence Database 
(http://microrna.sanger.ac.uk/sequences), a searchable database of published miRNA 
sequences and annotations.  
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MiRNAs are small RNAs, averaging from 20-23 nucleotides in length, performing diverse 
biological functions, often in a tissue-specific manner. They function by guiding sequence-
specific gene silencing at the transcriptional and/or post-transcriptional level (Bartel, 2004). 
In particular, these natural RNA-silencing processes can be harnessed to induce gene-specific 
silencing through the supply of non-natural RNA precursors or mimics of natural, small RNA 
processing intermediates. This approach, known as RNA interference (RNAi), is widely used 
for the systematic analysis of gene function, and its potential therapeutic applications are 
currently under intense investigation. However in order to efficiently harness the machinery 
of RNAi, it is essential to discover how the different types of small RNA molecules are 
generated. 
 
 
1.1.2 miRNA Biogenesis   
 
Most miRNAs were found to be transcribed at relatively large distances from coding regions. 
Therefore, they are likely to be transcribed as independent transcriptional units. On the other 
hand, some miRNA genes were found to be transcribed within introns of coding regions, and 
are orientated in the same direction, enabling them to be transcribed simultaneously without 
the need of a personal promoter. Some miRNAs are located in clusters, and are transcribed as 
one large multi-cistronic primary transcript, that is further processed into mature miRNAs. 
The mechanism by which miRNA biogenesis is evolutionarily conserved involves several 
sequential downprocessing steps performed by endonucleolytic cleavages (Lagos-Quintana et 
al., 2001; Lau et al., 2001). 
 
MiRNAs are initially transcribed in the nucleus by a RNA polymerase-II or RNA 
polymerase-III, forming large primary transcripts called pri-miRNAs (500-3000 nucleotides) 
(Figure 1) (Cai et al., 2004; Lee et al., 2004). They are assembled and processed by different 
endonucleases. Further processing and maturation of this pri-miR takes place in two 
sequential steps, which are initially processed in the nucleus, and subsequently exported into 
the cytoplasm. First, the pri-miR is cleaved by Drosha/DGCR8 into an approximately 60-80 
nucleotides long structure, and processed into a smaller precursor miRNA (pre-miRNA), that 
is typically characterized by a hairpin structure. This hairpin structure is exported out of the 
nucleus by exportin-5 (XPO5), into the cytoplasm of the cell. The pre-miRNA is then cleaved 
by Dicer1 (DCR-1) into a small imperfect double stranded miRNA-miRNA* duplex, that 
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contains both mature miRNA and its complementary strand miRNA*, with an average length 
of 22 nucleotides. The mature miRNA is incorporated into the miRNA Induced Silencing 
Complex (miRISC), while the complementary strand is degraded (Bartel, 2004; Lau et al., 
2001). 
 
 
Figure 1. MiRNA biogenesis. Pri-miRNA (a 60-80 nucleotide hairpin stem-loop) is transcribed from 
the miRNA gene by RNA polymerase II or III and then cleaved by Drosha/DGCR8 complex to 
generate a pre-miRNA (with a 22-bp stem and a 2-nucleotide 3’ overhang) in the nucleus. After being 
exported from the nucleus to the cytoplasm by Exportin-5, pre-miRNA is further cleaved by Dicer to 
remove the terminal loop. After unwinding, one strand of miRNA acts as the functional guide strand 
and binds to the target mRNA. The complementary strand (i.e., mRNA*) is rapidly degraded (Sun et 
al., 2010).  
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1.1.2.1 Working Mechanism  
 
Once the mature miRNA is loaded into the miRISC, it functions as a guide that directs the 
miRISC to the complementary sites of the 3’Untranslated Region (3’UTR) transcript 
sequences, in order to regulate gene expression. The miRISC can regulate target genes in two 
ways, depending on the degree of complementarity between the miRNA and the 3’UTR of the 
target mRNA (Figure 2).  
In plants these complementarities have to be very specific, meaning that the degree of 
complementarity has to be exact. This ultimately leads to the degradation of the target 
sequence. In animals, miRNAs can exercise their mechanism through two different paths 
depending on the degree of complementarity between miRNA and its target sequence. 
Translational repression occurs when partial complementarity is established between a 
miRNA and its 3’UTR of the target sequence. On the other hand, when total complementarity 
is found, degradation of the mRNA sequence takes place.   
   
Figure 2. Mechanisms of functional miRNA targeting. The 7-nucleotide seed region, which starts at 
the second nucleotide from the 5’ end of the miRNA, is required for miRNA-mRNA interaction. The 
miRNA-mRNA targeting occurs predominantly at the 3’UTR of the target mRNA, located at the 3’ 
downstream of the ORF. Bulges or mismatches may be present in the middle part of miRNA-mRNA 
duplex. As shown in the oval on the lower left, perfect base pairing between miRNA and mRNA 
(mostly plant cells) results in miRISC-mediated endonucleolytic cleavage and hence mRNA 
degradation. Despite the lack of complete complementarity in animal cells shown in the lower right, 
base pairing (particularly the 13-16 nucleotides of miRNA) is still important in stabilizing the 
miRNA-mRNA interaction, which leads to translational repression. Frequently, multiple miRNAs (red 
and blue) can target the same 3’UTR. Conversely, a unique miRNA may target multiple binding sites 
on the same 3’UTR in animal cells (Sun et al., 2010). 
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Expert and experimental bioinformaticians have been able to indicate which specific 
sequences are crucial for the correct target recognition of the miRNA. This region is located 
at the proximal 5’ region of the miRNA, and has been defined as the seed region. This seed 
sequence is located from the 2nd nucleotide to the 8th nucleotide of the miRNA, and has been 
shown to be important for biological function and stability. The region located at the 3’UTR 
of the target mRNA sequence that is complementary to the miRNA seed region, is called the 
miRNA recognition element (MRE). The MRE can display several degrees of 
complementarity towards the miRNA seed. When 6 nucleotides on the MRE (hexamer 6m) 
are complementary towards the seed region of a miRNA, it is considered to generate the least 
efficient miRNA-target recognition, and thereby least stable binding. Most target-miRNA 
recognition sites display this complementarity, but have an additional adenosine nucleotide 
located across from the 3’UTR end of the miRNA (7m-A1), or have an additional nucleotide 
located at the opposite 5’ end (7m-8m). The most efficient miRNA-target interaction was 
established when both the adenosine at the 3’UTR, as well as the additional nucleotide 
located at the 5’UTR, are found on the MRE (Bartel, 2009; Sun et al., 2010). 
 
Base pairing between the 3’UTR of the miRNA and the target mRNAs is not always essential 
for suppressing the target sequence, but if this does occur in this region, it can compensate for 
weaker seed binding and even increase the suppression. Above all, several MREs can be 
found on the 3’UTR of target sequences for one specific miRNA, or even several different 
miRNAs, leading to an intricate and complex manner in which mRNAs can be regulated. This 
can lead to either synergistic or antagonistic effects during repression of target genes. Finally, 
sequences surrounding the MRE and their accompanying secondary structures of the 3’UTR, 
can influence the access of the miRISC to the target region, whereby improper folding of 
these RNA regions can cause inefficient binding of the miRNA to its target 3’UTR (Liu et al., 
2008).   
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1.1.2.2. Predictions of miRNA target genes 
 
Bioinformatic algorithms have been designed to track down potential targets of miRNAs, and 
predicted that a single miRNA can influence up to 200 genes (Esquela-Kerscher and Slack, 
2006). Other estimations predict that 60% of all protein coding genes are influenced by 
miRNAs (Friedman et al., 2009). It has been postulated that a large number of genetic 
pathways are influenced by miRNAs, and that deregulation of miRNA expression could lead 
to aberrant cell metabolism and disease, including cancer. Till date only a fraction of these 
predictions have been experimentally confirmed but the exponential rise in miRNA 
publications might increase confirmations, differentiating the correct predictions from the 
eratic ones.  
 
The identification of miRNA target genes in plants has proven to be quite straightforward, 
since these genes need strict complementarity between miRNA and 3’UTR of target genes. 
This exact complementarity is rarely found in animals, making this approach for finding 
potential targets almost impossible. The first generation bio-informatic algorithms designed to 
find potential miRNA target genes, used the complementarity of the seed sequence as the 
foremost criteria for selecting target genes. This gave rise to a substantial amount of positive 
hits. Additional methods to enhance the successful prediction analysis were obtained by 
observing conserved MREs between different species. In this manner, selecting for these 
conserved sequences between species, an increase of positive hits was obtained (Bartel, 
2009). 
 
Even though there has been a progressive increase of experimental validation of miRNA 
target genes, a majority of miRNA targets still remain unknown. Till date the prediction 
algorithms remain the sole source for quickly screening a massive amount of genomic data. 
Such in silico analyses have the potential to find bona fide miRNA target genes, and have 
greatly improved the quality of prediction data (Chi et al., 2009; Tan et al., 2009). 
 
 
 
 
 
 
14 
 
1.1.3 Global importance of miRNAs in skin morphogenesis 
 
Skin morphogenesis is the biological process that accounts for the development, cell growth, 
and cellular differentiation of the largest organ on the human body. According to our genetic 
“blueprint”, this results in establishing the form and structure of a protective barrier that 
protects the body against environmental hazards, and prevents the loss of essential body 
fluids.   
 
The initial attempts to determine the significance of miRNA regulation in mammalian skin 
were aimed at targeting critical components of miRNA biogenesis. This was achieved by 
ablating a crucial gene that encodes the miRNA-processing enzyme Dicer, thus leading to a 
global depletion of all mature miRNAs. However, Dicer knockout is accompanied by 
embryonic lethality, and the embryo is rejected around embryonic day 7.5 (E7.5), which is 
prior to the initiation of skin development. To bypass this problem Cre-Lox recombination 
technology was employed creating a conditional knockout (cKO) of Dicer, which involves 
splicing out the Dicer sequence driven by a keratin-14 specific promoter (Andl et al., 2006; 
Yi et al., 2006). Thus, it became possible to remove Dicer from embryonic skin 
stem/progenitor cells starting around E13.5, when the keratin-14 specific promoter becomes 
active. Due to the long half life of miRNAs, mature miRNAs are not completely depleted 
until E17.5, which then enabled scientists to monitor and examine the consequences of 
complete loss of miRNAs during skin development (Yi and Fuchs, 2009). Additionally, the 
depletion of miRNAs was only achieved after the formation of the first suprabasal layer in the 
epidermis between E13 and E15, including the first wave of hair morphogenesis. Mice with 
the epidermal specific deletion of Dicer cKO gave birth to pups indistinguishable from 
control littermates. However, shortly after birth Dicer cKO pups begin to lose weight and 
neonatally die without developing a hair coat (Andl et al., 2006; Yi et al., 2006). Histological 
examination of these Dicer cKO pups revealed hair follicles (HF) that were underdeveloped, 
misaligned, and showed increased apoptosis. They also displayed a striking appearance of 
HFs that evaginate upwards instead of invaginating into the dermis, resulting in the formation 
of hair cysts. These evaginating HFs attract dermal papilla (DP), which migrate with them, 
maintaining the physical interaction and communication between HFs and DPs. The inability 
to maintain normal HFs located at the epithelial side of the epithelial-mesenchymal 
communication, suggests that these defects originate from deregulation of miRNA gene 
expression caused by loss of function of Dicer. Correspondingly, when examining identical 
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Dicer cKO in other stratified epithelial tissues such as in the tongue and footpad, similar 
defects were observed during morphogenesis, suggesting that miRNAs are critical for 
maintaining the correct morphogenesis of stratified epithelial tissues. In a following study a 
cKO was achieved through a mutation of another essential cofactor of miRNA processing, 
DGCR8. Identical phenotypes were observed such as those in Dicer cKO, including the 
evaginating HFs, enriched apoptosis in hair bulbs, rough and dehydrated skin and neonatal 
lethality (Yi et al., 2009). DGCR8 is known to be essential for the processing of stereotypical 
miRNAs, whereas Dicer was reported to be required for the processing of several classes of 
small RNAs, including miRNAs and miRNA-derived siRNAs. When analyzing deep 
sequencing reads of the different classes of small RNAs in Dicer cKO and DGCR8 cKO 
skins, the production of stereotypical miRNAs was shown to be equivalent in Dicer and 
DGCR8. However, the production of a few hairpin miRNAs and miRNA-derived siRNAs is 
only dependent on Dicer and not DGCR8 processing. This demonstrates more clearly that the 
acquired Dicer cKO phenotypes are indeed the result of loss of function of miRNAs in the 
skin and that the stereotypical miRNA are the most abundant Dicer products in the skin. 
 
These studies involving Dicer and DGCR8 cKOs in skin development attributed and 
accentuated the global importance that miRNAs play during skin morphogenesis, 
maintenance of HFs, epidermal proliferation and apoptosis. Clearly, the next step was to 
determine which individual miRNA, or which miRNA families, were responsible for these 
abnormalities during skin morphogenesis. 
 
The skin specific miR-203 is involved in the transition of epidermal cell proliferation from the 
basal layer into keratinocytes, and the upper stratified layers. During epithelial stratification, 
which takes place between embryonic days 13.5 to 15.5, miR-203 shows a 25-fold increase in 
expression in cells laying just above the proliferative basal cell layer. In the basal layer where 
undifferentiated epidermal stem cells reside, p63 is highly expressed to promote proliferation. 
Once the epidermal progenitors become suprabasal, miR-203 kicks in to repress the 
expression of p63. Consequently, these cells are able to exit cell cycle regulation, enabling the 
terminal differentiation phase (Koster et al., 2004; Yi et al., 2008). 
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1.1.4 miRNAs in skin diseases 
 
1.1.4.1 miRNA and psoriasis 
 
Psoriasis is the most prevalent human hyperproliferative autoimmune skin disease, 
characterized by an abnormal accelerated keratinocyte differentiation, reduced apoptosis, as 
well as pro-inflammatory responses. This is due to the aberrant cross-talk between the 
immune system and the structural cells of the skin, constituted by the production, infiltration, 
and inflammation of epidermal lymphocytes, neutrophils and dendritic cells (Lebwohl, 2003; 
Lowes et al., 2007; Sonkoly et al., 2007). Clinically, this leads to formation of psoriatic 
lesions that appear as erythematous plaques with silver-white scales. The percentage of the 
population that is affected by this disease varies from 0.3 to 3% in populations with different 
ethnic background (Griffiths and Barker, 2007). Psoriasis is a chronic and complex genetic 
inflammatory skin disease, with lesions displaying dramatically altered transcriptomics, 
revealing 1300 differentially expressed proteins (Gudjonsson et al., 2010; Zhou et al., 2003). 
However, little is known about the expression and the role of ncRNAs, such as miRNAs in 
psoriatic skin.  
 
To date, several miRNA expression patterns have been distinguished in healthy skin and 
psoriasis. This has indicated a new regulatory mechanism of miRNAs in the pathogenesis of 
chronic skin inflammation in psoriasis. The keratinocyte expressing miR-203 was the first 
miRNA to be described as overexpressed in psoriasis. The increased miR-203 coincides with 
the down-regulation of a predicted target gene known as suppressor of cytokine signaling-3 
(SOCS-3). SOCS-3 protein influences the inflammatory responses and keratinocyte 
proliferation and differentiation, by inhibiting the signal transducer and activator of the 
transcription 3 (STAT3) pathway. STAT3 is constitutively activated in epidermal 
keratinocytes of human psoriatic lesions, and is widely expressed by various growth 
regulating signals and inflammatory cytokines such as interleukin-6, which is present in 
psoriatic lesions. It is suggested that the SOCS-3 suppression by up-regulation of miR-203, 
leads to the constant activation of the STAT3 pathway. This results in the subsequent 
infiltration of immune cells, and development of psoriatic plaques through keratinocyte 
hyperproliferation (Sonkoly et al., 2007).    
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In contrast, in mouse skin a hypoproliferative effect is observed when miR-203 is up-
regulated. This anti-proliferative effect of miR-203 is puzzling, and leads to questions on 
target interaction, since miR-203/SOCS-3 target interaction could not be demonstrated (Lena 
et al., 2008). As stated above, miR-203 is implicated in the induction of cell cycle exit, and in 
repressing “stemness” in epidermal progenitors by targeting the transcription factor p63. Yet 
in psoriasis p63 was not found to be down-regulated at mRNA level. However, when 
observing protein levels of p63, down-regulation was demonstrated, confirming the likelihood 
of the miR-203/SOCS-3 interaction. These observations are compelling enough to warrant 
further investigations into the influence of miR-203 on the pathogenesis of psoriasis. 
Interestingly, a recent publication reports a novel antisense miRNA derived from the miR-203 
locus, which has been designated miR-203-AS (anti-sense) (Joyce et al., 2011). Next 
generation sequencing techniques were able to detect this new sequence, and even though it is 
much less abundant than miR-203 in skin, it is the most abundant novel miRNA included in 
this new data set. These findings suggest a role for miR-203-AS in psoriasis, but do not 
exclude the possible involvement of miR-203. Further functional characterization of miR-
203-AS will help to accommodate any inconsistencies concerning miR-203 and psoriasis.  
 
Two other psoriasis-specific miRNAs, namely miR-146 and miR-125b, show interesting 
potential for future treatments involving miRNA-based therapies against psoriasis. Both are 
involved in the tumor necrosis factor-alpha (TNF-α) pathway, with considerable success in 
contending psoriasis with the use of TNF-α blockers. First, miR-146 was shown to be 
overexpressed in psoriatic lesions and in patients that have rheumatoid arthritis (Pauley et al., 
2008; Sonkoly et al., 2008). Several miR-146a targets have already been identified such as 
TNF receptor-associated factor 6 (TRAF6) and IL-1R-associated kinase (IRAK). These genes 
are involved in the TNF-α pathway that contributes to psoriatic skin inflammation. 
Furthermore, it has also been demonstrated that the TNF-α pathway is inhibited by NFkappaB 
activation, which in turn has been linked to the up-regulation of miR-146a, thus potentially 
contributing to the disease state (Taganov et al., 2006; Tang et al., 2001). Secondly, miR-125b 
is down-regulated in psoriasis, and it has been suggested to post- transcriptionally regulate the 
TNF-α pathway (Tili et al., 2007). Through the loss of function of miR-125b, an increase in 
TNF-α expression is induced in psoriatic lesions.  
 
For other miRNAs involved in psoriasis we refer to reviews of (Bostjancic and Glavac, 2008; 
Joyce et al., 2011; Sonkoly et al., 2008) and Table 2. 
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1.1.4.2 miRNA and atopic dermatitis   
 
Atopic dermatitis is a chronic, relapsing, non-contagious, inflammatory skin disease that is 
characterized by pruritic (itchy), and eczematoid skin lesions. An initial study, determined to 
explore the role of miRNAs in this pathogenesis, discovered that in lesional skin of patients 
with atopic dermatitis, miR-155 is one of the most upregulated miRNAs (Sonkoly et al., 
2010). MiR-155 is regulated by T-cell activation signals in vitro, and by important trigger 
factors of atopic dermatitis in vivo. Sonkoly et al. (2010) were able to show that miR-155 is 
involved in the regulation of T-cell responses, by suppressing CTLA-4, and by enhancing T-
cell proliferation.  
 
In conclusion, these disease-specific miRNAs, together with others that have been identified, 
may well offer a potential for therapeutic targets in future applications against chronic 
inflammatory skin diseases.   
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 Table 2. miRNAs in chronic skin disease (AD: atopic dermatitis, RA: rheumatoid arthritis) 
miRNA’s Conditions Level Target genes Function Cell types 
miR-99a Psoriasis 
(Lerman et al., 
2011) 
 
↓ IGF-1R 
(Lerman et al., 
2011) 
 
Elevation of IGF-1R 
drives tissue towards 
proliferation 
KC 
miR-125b Psoriasis 
(Sonkoly et al., 
2007; Xu et al., 
2011) 
↓ FGFR2 (Xu et 
al., 2011) 
 
 
TNFA (Tili et 
al., 2007) 
Potentially reduces 
keratinocyte 
proliferation, 
Innate immune 
response, TLR 
signaling 
Fibroblasts, 
melanocytes, 
(KC’s) 
(Sonkoly et 
al., 2007) 
AD (Sonkoly et 
al., 2007) 
↓   
miR-146a Psoriasis 
(Sonkoly et al., 
2007)  
↑ TRAF6/IRAK1 
(Taganov et al., 
2006) 
Regulates TNFA 
signaling (Taganov et 
al., 2006) 
Immune cells 
(T-Reg, 
DC’s, mast-
cells) 
(Sonkoly et 
al., 2007) 
AD (Sonkoly et 
al., 2007)  
RA (Nakasa et 
al., 2008) 
↑ 
miR-155  AD (Sonkoly et 
al., 2010) 
RA (Pauley et 
al., 2008) 
Psoriasis (?) 
↑ CTLA-4 
(Sonkoly et al., 
2010) 
MMP-3 
Pu.1 (Pauley et 
al., 2009) 
SOCS1 (Lu et 
al., 2009) 
Innate/adaptive 
immune responses, 
germinal center 
response, IgG Class-
Switch (Pauley et al., 
2009) 
 
miR-203 Psoriasis 
 
 
 
↑ SOCS3  
(Sonkoly et al., 
2007) 
 
 
Sustained activation 
of STAT 3  
inflammation,  
May increase 
keratinocyte 
proliferation 
 
KC 
Normal 
epithelial cell 
biology  
↓↑ p63 (Lena et al., 
2008) 
Switch between 
proliferative capacity 
KCs and commitment 
to differentiation 
 
miR-
221/222 
Psoriasis ↑ TIMP3 (Zibert 
et al., 2010) 
Effect on MMP and 
epidermal 
proliferation 
 
 
Tumors (eg. 
Melanoma) 
(Felicetti et al., 
2008) 
↑ c-kit receptor 
p27 
Inducers of 
proliferation and 
tumorigenicity 
(Mercatelli et al., 2008) 
 
miR-424 Psoriasis ↓ MEK1, cyclin 
E3 (Ichihara et 
al.) 
KC hyperproliferation KC 
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1.1.5 miRNAs and UV stress 
 
When cells are exposed to various stresses, multiple mechanisms are induced to cope with 
such attacks. These include induction of molecular chaperones, rapid clearance of damaged 
macromolecules, growth arrest, and activation of specific gene expression programs. When 
cells can no longer deal with the excessive damage that has been induced, apoptotic pathways 
come into effect to clear out decimated cells. MiRNAs have emerged as key regulators that 
respond to various stress induced factors, such as ultraviolet radiation (UVR).   
 
Several studies have tried to find the role of miRNAs in responses inflicted by UVR. Studies 
in plants have established certain miRNAs that respond to such stresses. One such study 
involving Arabidopsis Thaliana, reports that 21 miRNAs genes in 11 miRNA families are 
differentially up-regulated in response to UVB stress (Zhou et al., 2007). A similar study 
involving Populus tremula, discovered 24 UVB responsive genes, that were classified into 3 
separate groups. The first group includes genes that are involved in signal cascades pathways, 
while the second group was more likely to target transcription factors via prediction 
databases. The third group of genes was involved in diverse physiological processes (Jia et 
al., 2009). 
 
Differential miRNA expression profiles have been observed when fibroblast (NIH3T3) 
received a UVB irradiation, as compared to non-UVB treated cells. A series of different time 
points associated with different miRNA expression profiles were analyzed (Guo et al., 2009). 
 
All these studies have shown the involvement of miRNAs in UVR. These, and forthcoming 
studies will enable elucidation of the cellular mechanisms underlying the UVR regulation of 
gene expressions, mediated by miRNAs. 
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1.1.6 Delivery of small RNAs into the skin 
 
Successful in vivo delivery systems for miRNAs are dependent on their resistance towards the 
degradation capacities of the skin, specificity to their targeted cells, and high binding affinity 
to the specific miRNAs in question. To enhance the stability of miRNAs three forms of 
chemical modifications can be used; 1) 2’-O-methyl group (OMe)-modified oligonucleotides; 
2) 2’-O-methoxyethyl-modified oligonucleotides; and 3) locked nucleic acid (LNA). 
Additionally, several techniques can be applied to aid in the delivery of miRNAs into the 
skin. Among these penetrating enhancing techniques such as tape-stripping, gene gun, 
intradermal injection with or without electroporation, and depilatory technology are 
commonly applied. A direct delivery of these compounds can also be used by intravenous 
injection or by formulation of RNA oligos together with lipophilic molecules ((Geusens et al., 
2011), cf. Addendum 1). A novel, unique and stable formulation was prepared in our lab, 
which could efficiently deliver siRNAs in cultured primary melanocytes and keratinocytes. 
These Secosomes were developed for siRNA delivery into the human skin (Geusens et al., 
2010), and since siRNA molecules and miRNA molecules differ ever so slightly from each 
other, experiments are ongoing to assess its application for miRNAs. 
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1.2 Human skin pigmentation 
 
1.2.1. Ultraviolet Radiation  
 
The terrestrial spectrum of solar UVR is located in the electromagnetic spectrum between 
ionizing x-rays and non-ionizing visible light, spanning a wavelength region of 100-400 
nanometers (nm). UVR is subdivided into three classes: shortwave ultraviolet-C (UVC),  mid-
wave ultraviolet-B (UVB) and long wave ultraviolet-A (UVA) (Diffey, 2002). The biological 
effects of each class vary with each accompanying wavelength.  
Long-wave UVA radiation ranges from 315-320 nm. UVA is not filtered by the stratospheric 
ozone layer in the atmosphere, through which approximately 90-99% reaches the earth 
surface. UVA has a long wavelength and low energy content, enabling it to penetrate deeper 
through the epidermis. Once considered to be harmless, it is now believed to be harmful if one 
has undergone excessive and long-term exposure. 
Mid-wave UVB spans a wavelength of 280/290-315/320 nm and is filtered by the 
stratospheric ozone layer in the atmosphere through which only 1-10% reaches the earth’s 
surface. Depletion of the ozone layer, enabling this medium wavelength radiation with its 
high energy content to reach the earth’s surface, this is an increased health concern. UVB 
penetrates the upper layers of the epidermis, and only 10-20% penetrates the dermis, but it is 
far more effective in causing sunburns than UVA. This wavelength is also responsible for 
tanning, wrinkling, photoaging and skin cancer. 
Short-wave UVC ranges from 100-200 nm, and is also filtered by the ozone layer in the 
atmosphere, but does not reach the earth’s surface.  
 
UVA and UVB radiation exercise different biological effects on the skin. Due to its high 
photon energy and shorter wavelength, UVB is more potent and effective in causing 
biological damage. It is estimated that UVB contributes to up to 80% of the harmful effects of 
sun exposure, while UVA only takes 20% for its account (Diffey, 1998). As indicated before, 
the penetration depth of these radiations also account for differences in biological effects.  
 
In order to apply in vitro studies with an artificial source, and to measure the effects that occur 
when human skin cells are exposed to sunlight, it is essential that sources and meters reflect 
the real world situation. This should provide quality and relevance to any in vitro 
photobiology experiment, and therefore researchers often opt to use a solar simulator as 
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artificial source of UV. A solar simulator represents the solar spectrum eventually reaching 
the earth. In particular UVC photons and also some very short UVB photons that never reach 
the surface of the earth are effectively eliminated by using a UVC blocking filter. Even 
though solar simulators do not cover the full spectrum, they are more representative than any 
other UV source (Gasparro and Brown, 2000). 
 
 
1.2.2 UV Induced Pigmentation 
 
Skin pigmentation in response to UVR has been classified into two time dependent reactions. 
The first reaction is considered to be the immediate pigment darkening (IPD), which is 
mainly stimulated by UVA radiation. This direct effect occurs within minutes, and persists for 
several hours, followed by a determined darkening that may last for several days. This tanning 
response is only transient, and is due to oxidation and polymerization of melanin precursors, 
including the redistribution of pre-existing melanosomes (Gilchrest et al., 1996; Honigsmann 
et al., 1986).  
 
The delayed tanning response (DT) is considered to be de novo synthesis of melanin 
(melanogenesis) and is mainly stimulated by UVB radiation, and to a lesser extent by UVA 
exposure (Parrish et al., 1982). This melanogenesis-based tan occurs several days after the 
initial UV exposure, but is more long-lasting. This tanning response takes more time to 
develop because of several transcriptional activation processes that are necessary to instigate 
the downstream melanogenic proteins, which will eventually lead to production of melanin. 
 
 
1.2.3 Melanogenesis 
 
1.2.3.1 Melanocytes and Melanin 
 
Evolution has entrusted melanocytes with the specific and very important task to protect our 
surrounding skin cells from the ever abiding presence of sunlight. These specialized cells that 
originate from neural crest cells, produce a pigmented biopolymer called melanin, which is 
essentially known as pigment, the primary determinant for our skin, hair, and eye color. These 
cells are present in the lower layer of the skin epidermis (stratum basale), middle layer of the 
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eye (uvea), inner ear, meninges, bones, and heart. The melanocytes in the skin are dendritic 
cells that are located at the junction of the dermis and the epidermis. These cells are known 
for their ability to produce and distribute melanin to the surrounding cells, which then 
function as a protective barrier against the harmful effects of UV radiation. They function 
either as a direct shield against UV and visible light radiation, or by absorption of free 
radicals. The photochemical properties of melanin aid against the stresses induced by UVR 
gained from sunlight. This photoprotectant absorbs harmful UVR and transforms its energy 
into heat, thus preventing the formation of free radicals that are accountable for mutagenic 
effects, responsible for the formation of malignant melanoma and other skin cancers. Inside 
these melanocytes reside specialized organelles, melanosomes, lysosome-like structures that 
are in charge of the synthesis of melanin. Melanosomes are translocated from the center of the 
melanocyte cytoplasm to the tips of its dendrites, where they are then transferred to the 
surrounding keratinocytes (Van Gele et al., 2009). 
 
Two major types of melanin exist in mammals: yellow-red pheomelanin and the black-
brown eumelanin. These types of melanin differ in size, shape, and packaging of their 
granules (Slominski et al., 2004). Eumelanosomes are elliptical, while pheomelanin shape is 
variable with a predominantly rounded contour. Gene mutations that lead to a loss of function 
are associated with increased pheomelanin production, which leads to lighter skin and hair 
color. Pheomelanin contains photo-unstable benzothiazines, which are potentially phototoxic, 
and may contribute to UV-induced skin damage, by generating free hydroxyl radicals and 
superoxide anions. It is also known to produce histamine, which contributes to erythema and 
edema. UV exposure reduces the level of glutathione reductase, which is important for 
pheomelanin synthesis. Eumelanin is considered to be more photoprotective because it has the 
ability to function as a superoxide dismutase, and is known for its ability to scavenge free 
radicals, which reduces reactive oxygen to hydrogen peroxide.  
 
Melanin biosynthesis is derived from a common tyrosinase-dependent pathway and is 
initiated either through hydroxylation of L-phenylalanine to L-tyrosine, or directly from L-
tyrosinase. Tyrosinase catalyzes the two rate limiting reactions of melanogenesis by 
hydroxylation of L-tyrosine, giving the 3,4-L-dihydroxyphenylalanine (L-DOPA), followed 
by the oxidation of L-DOPA into dopaquinone. From here on the eumelanogenesis and 
pheomelanogenesis pathways diverge from each other. Eumelanogenesis involves the 
transformation of dopaquinone into leukodopachrome, and after several subsequent 
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oxidoreduction reactions produce the intermediates dihydroxyindole (DHI) and DHI 
carboxylic acid (DHICA), that finally undergo polymerization steps to form eumelanin. 
Initially, pheomelanogenesis also starts with dopaquinone but is alternatively conjugated with 
cysteine or glutathione to yield cysteinyldopa and glutathionyldopa, which is further 
processed and transformed into pheomelanin. 
 
1.2.3.2 Molecules that induce pigmentation 
 
Exposure of skin to UV results in increased synthesis of paracrine factors from keratinocytes 
and fibroblasts, which can stimulate pigmentation by secreting growth factors that act via 
receptors located on melanocytes. The activation of the melanocortin-1-receptor (MC1R) is 
the start of one of the main signaling pathways, which accompanies UV-induced 
melanogenesis, and is mediated by an increase in intracellular cyclic adenosine 
monophosphate (cAMP) levels.  
The cAMP signaling pathway is a key physiologic regulator, and has been known to activate 
protein kinase A and CREB proteins (Im et al., 1998). This eventually upregulates the 
expression of MITF, a key transcriptional regulator that controls the expression of 
melanogenic enzymes and proteins. The fact that cAMP has been shown to stimulate dendritic 
formation (Busca et al., 1998), aids in transport of melanosomes into the dendritic tips 
(Passeron et al., 2004), and increases the gene expression of a known transport protein acting 
at the peripheral actin filaments, Rab27a  , makes it pivotal for UV-induced melanogenesis 
(Chiaverini et al., 2008).  
 
Certain hormones and chemical agents are commonly used to raise intracellular levels of 
cAMP. α-melanocyte stimulating hormone (α-MSH) for example, is a naturally-occurring 
endogenous peptide hormone, while forskolin, is a labdane diterpene that is produced by the 
tropical perennial plant Indian Coleus (Coleus forskohlii). They have the capacity to decrease 
UV-induced apoptosis of melanocytes, and to increase pH levels (alkalinization) of 
melanosomes, which aids in the stimulation of enzymatic activity during melanin synthesis 
(Bohm et al., 2005; Hauser et al., 2006; Kadekaro et al., 2005). Melanogenic stimulators such 
as forskolin are often used in combination with UV to stimulate melanogenesis (D'Orazio et 
al., 2006). 
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One of the important mediators of pigmentation is the large precursor protein pro-
opiomelanocortin (POMC) that is stimulated by p53 and secreted by keratinocytes upon UV 
irradiation (Cui et al., 2007). POMC produces several derived peptides by proteolytic 
cleavage, including α-MSH, adrenocorticotropic hormone (ACTH), isobutylmethylxanthine, 
and dibutyryl cyclic adenosine monophosphate (cAMP) (Chakraborty et al., 1996).  
 
The effects of α-MSH on melanogenesis are regulated via tyrosinase and MC1R. This 
receptor gene is one of the most important positive regulators, regulating the intensity as well 
as the type of melanin produced during melanogenesis. MC1R is also a major determining 
factor in sun sensitivity, and a genetic risk factor for melanoma and non-melanoma skin 
cancer. Over 30 variant alleles have been identified which correlate with skin and hair color, 
providing evidence that this gene is an important component in determining normal human 
pigment variation 
MC1R (or MSH-R) is an intronless gene that encodes a receptor protein for α-MSH (see 
figure 3). The encoded protein contains a seven pass membrane G protein coupled receptor 
that controls melanogenesis. When binding of MC1R protein on the plasma membrane of 
melanocytes and α-MSH protein located in extracellular space occurs, the activation of this 
receptor and stimulation of eumelanin synthesis follows (Goding, 2000; Manne et al., 1995). 
Inside the cytoplasm, the Gαs protein binds onto the activated MC1R protein (Vongs et al., 
2004). Gαs protein increases activation of adenylate cyclase (AC) (Costin and Hearing, 2007). 
This in turn increases one of the critical factors involved in the signal transduction pathway of 
melanogenesis, known as cAMP. cAMP is formed by AC through catalyzing the following 
reaction: ATP -> cAMP (Busca and Ballotti, 2000; Goding, 2000). Due to the increase of 
intracellular cAMP concentration, activation of protein kinase A (PKA) complexes are 
induced (Costin and Hearing, 2007). cAMP binds to two sites of the regulatory subunit of 
PKA, allowing the catalytic subunit to be liberated, and thus activated (Roesler et al., 1998). 
Activation of PKA allows it to relocate into the nucleus, where it phosphorylates and activates 
the cAMP responsive element binding proteins (CREB), and CREB binding proteins (CBP) 
(Costin and Hearing, 2007). CREB proteins activate the expression of certain downstream 
genes containing consensus CRE (cAMP responsive elements) sequences in their promoter 
(5’TGACCTCA-3’) regions (Karin, 1994). As such, CREB binds to the CRE domain present 
on the promoter of the important transcription factor MITF, which plays a fundamental role in 
the transcriptional regulation of melanogenesis.  
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Microphthalmia-associated transcription factor (MITF) is a transcription factor that 
contains both basic helix-loop-helix and leucine zipper (bHLH-Lz) structural features, which 
drive important pigmentation genes such as tyrosinase. The two major signaling pathways 
that control MITF activity are the MSH/cAMP pathway and Kit signaling pathways (Figure 
3).  
Another protein that is stimulated by MITF is tyrosinase-related protein 1 (TYRP1), which 
encodes a melanosomal enzyme that belongs to the tyrosinase family, and plays an important 
role in the melanin biosynthetic pathway. Tyrosinase-related protein 2 (TYRP2) also 
known as dopachrome tautomerase (DCT), is a protein that is up-regulated by MITF 
(Bertolotto et al., 1998). 
 
Genes that regulate the expression of MITF include PAX3 and SOX10. PAX3 is a member of 
the paired class homeodomain family of transcription factors. PAX3 both promotes and 
inhibits melanogenessis through transcriptional regulation of MITF, DCT and TYRP1 
(Goding, 2000; Vance and Goding, 2004). SOX10 is a gene that encodes a member of the 
SOX (SYR-related HMG-box) family of transcription factors involved in the regulation of 
embryonic development, and in the determination of the cell fate. The encoded protein may 
act as a transcriptional activator after forming a protein complex with other proteins. In nuclei 
of melanocytes, SOX10 protein increases expression of MITF protein (Goding, 2000; Vance 
and Goding, 2004). 
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Figure 3. Melanocyte pigmentation signaling. Kit signaling pathway and MSH pathway. 
(PP) Protein-Protein interactions, A) Activation, (EC) Reaction, (P) Phosphorylation, (RE) Reaction,  
(E) Expression 
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Kit signaling up-regulates MITF function through mitogen activated protein kinase (MAPK) 
phosphorylation. Kit is a membrane bound receptor of the receptor tyrosine kinase (RTK) 
family, which constitutes a type III transmembrane receptor protein-tyrosine kinase for MGF 
(mast cell growth factor, also known as stem cell factor (SCF)) (Roskoski, 2005). Kit receptor 
in plasma membrane from melanocytes is activated by binding to its ligand SCF in 
extracellular space (Hachiya et al., 2001) (Figure 3). SCF encodes for a ligand of the tyrosine-
kinase receptor encoded by the KIT locus. On the cell surface of melanocytes, SCF binds to 
the extracellular portion of c-KIT receptor, thus mediating dimerization of two subunits 
located at the inner side, followed by activation of its intrinsic tyrosinase kinase activity, and 
auto-phosphorylation. The autophosphorylated tyrosine residues serve as docking sites for 
various signal transduction molecules containing SH2 domains. The activated KIT receptor 
phosphorylates various substrates and associates with various signaling molecules.  
In the cytoplasm of melanocytes, GRB2 binds to the phosphorylated c-KIT present in the 
plasma membrane of melanocytes. Next, GRB2 binds to the guanine nucleotide exchange 
factor protein, son of sevenless (SOS), which is then able to bind to the inactive membrane 
bound protein Ras. Inactive Ras is bound to the nucleotide guanine diphosphate (GDP). In 
order to activate the Ras protein, SOS catalyses the exchange of the Ras bound guanine GDP 
against guanine triphosphate (GTP). Due to this exchange to its active GTP bound state, Ras 
is able to bind to several effector proteins. Hereafter, SOS protein increases the activation of 
Ras protein (Costin and Hearing, 2007). This Ras protein increases activation of cellular Raf 
(c-Raf) protein, which is a cellular homolog of viral raf gene, and is one of the important 
effectors of Ras. c-Raf encoded protein is a MAP kinase kinase (MAP3K), which functions 
downstream of the Ras family of membrane associated GTPase to which it directly binds. 
Once activated, the c-Raf protein can phosphorylate to activate the dual specificity protein 
kinases MEK1 and MEK2, which in turn phosphorylate to activate the serine/threonine 
specific protein kinases, ERK1 and ERK2, which all lead to the activation of the RAS-MAPK 
pathway (Anjum and Blenis, 2008; Costin and Hearing, 2007). MAPK pathway may directly 
activate MITF, or it may activate indirectly via p90RSK1 (Goding, 2000; Vance and Goding, 
2004). Additionally, p90RSK1 proteins increase phosphorylation and activation of CREB 
proteins in nuclei from melanocytes.  
Activated MITF pairs with the co-activator p300/CPB. Once this complex is formed, several 
gene expression levels can be regulated. MITF-p300/CBP complex increases expression of 
anti-apoptotic BCL2 protein, leading to cell survival (McGill et al., 2002). This gene encodes 
an integral outer mitochondrial membrane protein that blocks the apoptotic death of some 
30 
 
cells. In addition, this MITF-p300/CBP complex increases the expression of tyrosinase (TYR) 
protein and pigmentation. TYRP1 protein is increased by the same MITF-p300/CBP complex 
and can subsequently increase pigmentation. Finally, DCT protein is also positively regulated 
by the MITF-p300/CBP complex, aiding in the increase of pigmentation. MITF 
phosphorylation also couples transactivation to proteasome mediated degradation. Kit 
signaling thus triggers short lived MITF activation and net MITF degradation. 
 
The Wnt signaling pathway has also been associated to melanogenesis, and initially works 
through binding of Wnt proteins to the cell surface receptor of the Frizzled family. This 
causes the receptors to activate Dishevelled family protein, which is a key component of the 
membrane-associated Wnt receptor complex. This activation subsequently inhibits a 
multiprotein complex containing axin, adenomatous polyposis coli (APC), casein kinase Iα 
(CKIα) and glycogen synthase kinase-3β (GSK3β). This protein complex promotes the 
continuous ubiquitin mediated degradation of an intracellular signaling molecule, β-catenin, 
leading to a low abundance of this molecule in the cytoplasma (Rubinfeld et al., 1996). Due to 
the deactivation of the complex containing GSK3β, the accumulation of β-catenin is 
permitted. One of the key factors of β-catenin is its stability. If stable enough it is translocated 
into the nucleus and binds to transcription factors of the T-cell factor Tcf/lymphoid enhancer 
factor (Lef) family, which then directly leads to the positive transcriptional regulation of 
MITF (Behrens et al., 1996; Peifer and Polakis, 2000).  
 
It has been demonstrated that the intracellular accumulation of cAMP levels resulting in 
activation of PKA can rapidly phosphorylate GSK3β, leading to its deactivation. 
Additionally, the direct phosphorylation of β-catenin by this cAMP/PKA signaling, and thus 
the inhibition of β-catenin degradation, increases Tcf-dependent transcriptional activity, 
followed by increase in MITF transcription (Hino et al., 2005; Suzuki et al., 2008). This 
shows how cross talk between different pathways during melanogenesis is ever present. 
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1.2.4 Intracellular melanosome transport 
 
Introduction  
Melanosome transport in melanocytes is considered to be a model system for the study of 
cytoskeletal regulation of intracellular transport and has contributed to a better understanding 
of the molecular mechanisms involved in vesicle transport and membrane trafficking 
processes. Melanosomes are transported from the nucleus to the cell periphery of the 
melanocytes by coordination between bidirectional microtubule-dependent movements and 
the unidirectional actin-dependent movement.  
Here we provide an in depth overview of all the essential players that help regulate this type 
of transport to date. We discuss how the gathered knowledge about the RAB27A-MLPH-
MYO5A tripartite complex can be translated into a possible therapeutic application to reduce 
(hyper)pigmentation of the skin. Mutations within any of the RAB27A-MLPH-MYO5A 
tripartite complex cause one of the three different subtypes of a rare autosomal recessive 
hereditary disease, known as Griscelli syndrome (GS), which develops early in life. A 
common characteristic found in these patients is hypopigmentation of skin and hair (Rees, 
2003).  
 
 
 
Review 
M. Van Gele, P. Dynoodt and J. Lambert. 
Griscelli syndrome: a model system to study vesicular trafficking.  
Pigment Cell Melanoma Res 2009; 22: 268-282. 
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1.2.5 Melanosome transfer 
 
To date, several hypotheses on how melanocytes transfer melanosomes into keratinocytes 
have been developed. Unfortunately, none of these described modes of transfer can be 
considered as conclusive. In the following we shall briefly describe these four modes of 
action (Figure 4) (Van Den Bossche et al., 2006).  
 
A. Cytophagocytosis is defined as the cellular engulfment of particles that have been pinched 
off from the dendritic tips of melanocytes. The dendritic tips containing mature melanosomes 
form protrusions into the keratinocytes’ cell membrane. These protrusions are engulfed by the 
closure of the keratinocytes membrane leading to the dispersion of melanin granules 
throughout its cytoplasm. 
 
B. Exocytosis is based on the cellular secretion of melanin out of the melanocytes followed by 
fusion of the melanosomal membrane with the plasma membrane of the keratinocyte, either 
through endocytosis or phagocytosis. 
 
C. The fusion method of the plasma membranes of both melanocytes and keratinocytes 
suggests the formation of pores or channels between both cell types. Melanosomes are 
transported through this connection. 
 
D. Membrane vesicles containing melanosomes are shed by the melanocytes followed by 
either fusion with the membrane of keratinocytes or ingestion through phagocytosis.   
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Figure 4. Different modes of melanin transfer 
A) Cytophagocytosis. B) Exocytosis. C) Fusion.   D) Membrane vesicles. 
M: melanocyte, K: keratinocyte 
 
 
1.3 Skin cancer 
 
Cancer is a disease characterized by malfunctioning of growth, differentiation and loss of 
sustainable tissue integrity. Cancer cells proliferate in an uncontrollable manner, and thus 
begin to invade into surrounding tissues, becoming metastatic. During metastases the cancer 
cell is able to loosen itself from the tumor, thus migrating freely through the blood stream and 
lymph nodes towards other locations of the body (Hanahan and Weinberg, 2000; Hanahan 
and Weinberg, 2011).   
 
Skin cancers are a collection of cancers that originate from epithelial cells of the skin (basal 
cell carcinoma (BCC) and squamous cell carcinoma (SCC)), or from melanocytes / pigment 
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cells of the skin (melanoma). Melanoma is the most aggressive type of skin cancer. It is a 
malignant injury that originates from melanocytes that are found at the basal layer of the 
epidermis. The melanin produced by melanocytes functions as a physiological barrier against 
UVR. In this manner melanocytes deposit the pigment into the surrounding keratinocytes, 
which then protect the DNA that is situated in the nucleus. This results in the protection of the 
keratinocytes from the influence of UVR. 
 
The incidence of all types of skin cancers in Western Europe has increased considerably 
during the past half century and it is expect that this incidence will only increase with the 
continuing aging of the population (Erb et al., 2008; Samarasinghe and Madan, 2012).  
 
BCC represents 70% of all skin cancers. Although the occurrence of this form of skin cancer 
is most prevalent, it is not registered in the cancer registration system because of its low 
mortality rate. BCC is characterized by an extensive local growth, which can damage the skin 
tissue. Surgery is the most efficient treatment, although there are alternative treatments for 
certain subtypes of BCC. SCC represents 20% of all skin cancers (Samarasinghe and Madan, 
2012). This skin cancer is caused by UVR, or in the case of immune suppression, can be 
found in transplant patients. This form of skin cancer has a metastatic potential, usually by 
first migrating to the lymph glands, and then further towards the internal organs 
(Samarasinghe and Madan, 2012). 
 
 
1.3.1 Melanoma 
 
Melanoma is the most aggressive skin cancer. Melanoma represents only 10% of all skin 
cancers and belongs to the five most frequent cancer type found in Belgian women. The 
incidence of melanoma has increased considerably in the second half of the 20th century. 
Although the incidence increases with age, it still affects a relatively young population 
compared to other cancer types. The prognosis of melanoma significantly correlates with the 
tumor thickness, therefore an early detection is crucial (Samarasinghe and Madan, 2012). 
Since observation of the skin by clinical surveillance with additional inspection by use of a 
dermatoscope, is relatively easy, and a noninvasive technique, it subjects melanoma to the 
early detection by screening preferably towards people at risk. With men melanoma is mainly 
found in the region of the torso, while with women the legs are the more prone sites.     
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Different forms of melanoma are known. The superficial spreading melanoma and the nodular 
melanoma are the most frequent types. Lentigo maligna melanoma and acral lentiginous 
melanoma are less frequent subtypes. Superficial spreading melanoma initially shows a 
horizontal growth phase with the possibility to grow inwards. Nodular melanoma is at a very 
early stage already growing vertically. Both subtypes are mainly caused by intermittent sun 
exposure (high UV exposures on a non regular basis). Lentigo maligna melanoma is a slow 
growing melanoma located on the surface of the skin, and is mostly associated with elderly 
who have been through chronic exposure to sun light, for example to the face. Finally, the 
acral lentiginous melanoma is mostly found at the exterior regions of the body for example 
the hand palms, foot soles, and nail beds.  
 
1.3.2 Role of miRNAs in melanoma 
 
Cancer is a complex genetic disease with structural chromosomal deviations and disturbed 
expression of coding genes as well as non-coding genes. Hanahan and Weinberg postulate 
that healthy cells that develop into cancer cells have to attain essential capacities to enable 
them to develop into a cancer cell; for example subsistence in growth signals, loss of growth 
inhibition substances, resistance to apoptosis, increase in angiogenesis, unlimited division 
capacity and metastasis (Hanahan and Weinberg, 2000). At the basis of these new properties 
lie the genetic deviations that are present through genetic hereditary or can be additionally 
induced by exogenous factors that are either chemical, physical or of an infectious nature 
(Weinberg, 2007). For example smoking of tobacco products can cause lung cancer, the 
exposure to UVR can contribute to the development of skin cancer, and cervix cancer arises 
after the infection of the human papilloma virus.  
 
The function of genes that affect cancer can be divided into two categories: the oncogenes, 
which play an active role during the progression of cancer by accelerating the growth 
controlling signaling pathways, and the tumor suppressors, which play a role during cell 
growth and attend to the DNA integrity and reparation of DNA damage. Gain-of-function by 
point mutations, amplification of chromosomal rearrangements, and the loss-of-function by 
point mutations or deletions of the respective oncogenes and tumor suppressors, insure that a 
cell may attain the aforementioned capacities and enable it to transform into a cancer cell 
(Calin et al., 2004).    
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MiRNA expression profiling studies have shown that normal tissues have distinguished 
miRNA expression signatures compared to their different tumor counterparts, including the 
different stadia that tumors go through. At this moment different diagnostic signatures have 
been made for lung tumors, breast cancer, glioblastoma, thyroid cancer, hepatocellular 
carcinoma, pancreatic cancer, colorectal cancer, and chronic lymphocytic leukemia (Calin and 
Croce, 2006). Expression of one or several miRNAs has been shown to correlate with general 
survival rates, post operative survival, and response to treatment and risks associated to 
metastasis (Calin and Croce, 2006). The involvement of miRNAs in tumor formation and the 
way they act as potential oncogenes or tumor suppressors has aroused great interest in the use 
of these molecules as potential therapeutic targets for cancer therapies. The general 
therapeutic strategies utilizing antisense mediated inhibition of oncomiRs and the substitution 
of microRNA mimics through viral vector coding miRNAs are interesting strategies that are 
actually being studied (Trang et al., 2008). 
 
In 2008, the first link between the deregulated expression of a specific miRNA and its 
function during oncogenesis of melanoma was established (Bemis et al., 2008). MiR-137 is 
located in the chromosomal region 1p22 and is known to carry alleles susceptible to 
melanoma. Increased expression of miR-137 represses the expression of MITF, which was 
also significantly decreased in uveal melanoma cells, with an additional decrease in cell 
growth through inducing G1 cell cycle arrest (Chen et al., 2011). MITF is an important 
regulator in development, maturation, apoptosis and pigmentation in melanocytes. Induction 
of MITF, for example when exposed to UV, protects the skin against DNA damage (Cui et 
al., 2007). MiR-182 also works as a negative regulator of MITF and FOXO3 expression. 
Increased expression of miR-182 has been associated with a rise in invasiveness of 
melanoma, increasing its metastatic potential (Segura et al., 2009). MiR-340 is also capable of 
binding to the 3’UTR of MITF causing mRNA degradation (Goswami et al., 2010).  
 
MiR-532-5p has been shown to be an oncomiR by directly targeting runt-related 
transcription factor 3 (RUNX3), which is a known tumor suppressor during the transition of a 
melanocyte into a metastatic melanoma (Kitago et al., 2009). It has also been shown that miR-
210 is upregulated in melanoma and breast cancer metastases that suffer from hypoxia (Zhang 
et al., 2009). MiR-210 targets MNT, which is a gene known as one of the Myc antagonists. 
The miR-200 family is increased in melanoma cell lines compared to normal melanocytes. 
The difference between each member of the miRNA family is the mode of invasion that each 
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miRNA instigates. MiR-200a for example, results in a protrusion-associated elongated mode 
of invasion by reduced actomyosin contractility, while miR-200c adopts a more rounded, 
amoeboid-like mode of invasion by reduced expression of myristoylated alanine-rich protein 
kinase C substrate (Elson-Schwab et al., 2010).  
 
MiR-34b, miR-34c, and miR-199a* have been identified as tumor suppressors in melanoma 
cells because they target an oncogene called MET, which encodes for a tyrosine kinase 
receptor for hepatocyte growth factor (Migliore et al., 2008). It has also been reported that 
miR-34 expression is aberrantly expressed due to CpG methylation of its promoter region 
(Lodygin et al., 2008). MiR-196a is significantly repressed in malignant melanoma cell lines 
and tissue samples, and when re-expressed in vitro, it is able to significantly reduce the 
invasive behavior of melanoma cell lines (Braig et al., 2010; Mueller and Bosserhoff, 2010). 
It has also been reported that the overexpressing miR-193b in melanoma cell lines repressed 
proliferation by down-regulating cyclin D1 (CCND1) (Chen et al., 2010).  
 
Recent developments that have given vast amounts of data are the miRNA expression profile 
studies that have been performed in melanoma. Through these studies miRNA signatures in 
melanoma have been defined. These data have clinical relevance as potential biomarkers as 
well as prognostic value into determining at what stage the melanoma has progressed (Segura 
et al., 2010).   
 
These miRNA signatures can not only be found in cancer tissues but also in blood. The 
possibility to detect which miRNAs are found in the patient’s blood offers perspectives for 
determining the present stage of the melanoma in a non-invasive manner (Leidinger et al., 
2010). 
 
It is beyond the scope of this PhD thesis to review all miRNAs that have been reported in 
melanoma. We have summarized most of the described miRNAs in Table 3 (Li and Xi, 2011). 
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Table 3. MicroRNAs in melanoma progression 
 
Progression  miRNA Target(s) Regulatory Factor Associations 
      
  let-7a ITGB3  ↓ Migration, invasion 
  let-7b CCND1  ↓ Proliferation, differentiation 
  miR-137 MITF  ↓ Cell migration, invasion and survival 
 ↓ miR-155   ↑ Proliferation 
Melanocyte   miR-324-5p     
  miR-34a MET Promoter methylation ↓Proliferation 
↓  miR-106a    
  miR-126    
Primary 
Melanoma  miR-133a    
  miR-141    
 ↑ miR-145    
  miR-15b   ↑ Proliferation, survival 
  miR-200c   Migration style transition 
  miR-27b    
  miR-210 MNT  ↑ Proliferation 
      
  miR-126    
  miR-200c    
  miR-141    
 ↓ miR-133a    
Primary 
Melanoma  miR-34a    
  miR-199a* c-Met  ↓ Cell migration, invasion and survival 
↓  miR-34b/c c-Met  ↓ Cell migration, invasion and survival 
      
Metastasis  miR-106a    
  miR-133a    
  miR-199a*    
 ↑ miR-182 MITF, FOXO3  ↑ Migration, invasion and survival 
  let-7b    
      
  miR-133a    
  miR-155   ↓ Proliferation, survival 
 ↓ miR-193b    
Melanocyte  miR-196a 
HOX-C8  
HOX-B7  ↓Invasion 
      
  miR-133a    
↓  miR-17-5p    
  miR-18a    
Metastasis  miR-19a/b    
 ↑ miR-221/222 c-Kit, p27 PLZF ↑ Proliferation, invasion; ↓     differentiation 
  miR-532-5p RUNX3  ↑Invasion 
  miR-20a    
 
 miR-92a    
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Aims  
 
Previous studies of the Dermatology Research Unit (DRU), at the Ghent University Hospital, 
focused on the role of motor proteins, such as Myosin VA (MYO5A), in primary human 
melanocytes and pigmentation. The DRU previously developed a method based on RNAi to 
reduce the expression of specific isoforms of the motor protein MYO5A, known to be 
involved in intracellular melanosome transport. The DRU succeeded in blocking melanosome 
transport in human melanocytes cultured in vitro, and thus reducing pigmentation by means of 
an exon F MYO5A siRNA formulation (Van Gele et al., 2008). In line with these studies a 
new emphasis was placed in this thesis on the discovery of new molecules, which could be 
manipulated in order to promote or reduce pigmentation. This was carried out by miRNA 
expression profiling of UV-irradiated melanocytes. 
 
Manipulation of miRNA expression or function, either by mimicking or inhibiting them, is 
emerging as an innovative, and highly promising therapeutic strategy. Moreover, intrinsic 
drawbacks with siRNA-induced gene silencing (including off-target effects, elicitation of 
interferon response, and interference with endogenous miRNA biogenesis) are eliminated 
when using miRNAs, due to their specific biogenesis and mechanism of action.  
The first objective of this thesis is to identify miRNAs involved in the pigmentary process 
in melanocytes, either by modulating the expression of miRNAs, decreasing pigmentation 
and thus potentially forming a basis for treatment against hyperpigmentation and melasma, or 
increasing pigmentation, and thus offering a better protection against the harmful effects of 
UV and melanoma development. This might lead to new insights into miRNA-based 
treatments, offering an attractive alternative by specifically targeting key genes in 
melanogenesis.  
In order to determine, which biological effects miRNAs have on the pigmentary process, and 
as a second objective, functional studies were performed with the most prominently 
influenced candidate miRNA from a miRNA profiling study, following an experimental 
model system (ssUV/forskolin). MiR-145 came out as a key player during melanogenesis, but 
has also frequently been reported to be down-regulated in various cancer types including 
prostate cancer (Fuse et al., 2011), bladder cancer (Chiyomaru et al., 2010), colon cancer 
(Akao et al., 2007b), and B-cell malignancies (Akao et al., 2007a). Accordingly, various 
miRNA profiling studies performed on malignant melanoma tissues have suggested a tumor 
suppressor role of miR-145 in melanoma (Segura et al., 2010). This miRNA is located on 
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chromosome 5q, which is a common deletion region found in melanoma (Lin et al., 2008). 
Therefore, as a third objective a possible key role of miR-145 in melanoma and its tumor 
suppression response on cell growth, invasion and migratory activity, was considered and 
explored.  
 
Outlines 
 
The specific role of miRNAs in pigmentation is not yet defined. In order to study the 
pigmentary process, a robust in vitro model system that monitors this process is required. An 
experimental model system that studies the effect of ssUV and forskolin was developed, 
based on the model system using a mouse cell line of normal immortal melanocytes, melan-a 
(Lei et al., 2002). This system was slightly modified in order to fit the desired responses. This 
model was used, in order to obtain a more complete understanding of this complex 
pigmentation process. After confirmation of several important upregulated pigmentation 
genes, we defined an experimental model system, ultimately capturing and registering 
differentially expressed miRNAs involved in pigmentation.  
 
By comparing miRNA profiles of treated melan-a cells (ssUV and forskolin), versus control 
melan-a cells, miRNA profiling was obtained through a qPCR-based method, using stem-loop 
primers. To obtain cDNA from all miRNAs present, a megaplex reverse-transcriptase primer 
pool of 10 ng of total RNA was used. The expression of 540 miRNAs, was then quantified 
through real-time qPCR, containing a Taqman probe library. After screening for miRNAs that 
affect the cellular pigmentary process in our model system, 16 differentially expressing 
miRNAs were retained. After consulting target prediction databases, one specific miRNA 
caught our attention, presenting not only several potential target binding sites to a gene 
involved in melanogenesis, but additionally showing a 15-fold knockdown compared to its 
control counterparts. Gain- and loss-of-function experiments involving miRNA precursors 
and miRNA inhibitors were used to mimic or inhibit this specific miRNA in an attempt to 
uncover biological effects that are influenced by miR-145. Western blotting was used to 
investigate the impact of this miRNA on protein expression, and real-time qPCR was used to 
quantify the gene expression levels of important genes during the pigmentation process. 
Luciferase target assays were designed and used to determine which direct targets are 
influenced by this miRNA. The results enabled us to confirm that this one specific miRNA 
plays a key role during the pigmentation process.   
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After establishing the role of miR-145 in melanocytes, and confirming its key role during the 
pigmentary process, we decided to investigate the potential tumor suppressor role of this 
miRNA in melanoma. MiR-145 has already been studied in several cancer types, and has 
been described as having a tumor suppressor role. Three cell lines were chosen with a 
different metastatic potential, and the expression level of miR-145 was quantified. Two 
metastatic cell lines, BLM and FM3P, demonstrated an extremely low expression level of 
miR-145, while a third and last primary melanoma cell line showed a slightly increased 
expression of this miRNA, as compared to normal human primary melanocytes. After 
overexpressing the miRNA in these melanoma cell lines, several functional studies were 
performed in order to investigate the tumor suppressor role of miR-145 in melanoma. Wound 
healing assays were performed in order to study the effect of the miR-145 on cell migration 
and cell interactions, while the Trypan Blue Exclusion Test of Cell Viability was used to 
determine if this miRNA influences cell proliferation. A collagen invasion assay was 
performed in order to determine the invasiveness of the melanoma cell lines into a collagen 
type-1 matrix. To uncover the mechanism of miR-145 as a tumor suppressor, knockdown 
studies on a direct target, FSCN1, of this miRNA were performed.  
 
In conclusion, the outlines of this thesis describe a useful and comprehensive strategy on how 
to uncover the involvement of miRNAs during melanogenesis and melanomagenesis. 
Moreover, we have established a strong platform to guide future research and promote further 
in depth studies.  
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3.1 Screening for potential miRNAs involved in pigmentation  
 
 
Introduction 
 
Production of melanin is controlled by multiple players whereby more than 150 genes have 
been identified. Knowledge of which specific role miRNAs execute during the regulation of 
the pigmentary process is very limited, till date. The following study is the first to perform an 
in depth miRNA expression profiling analysis in an attempt to unravel the role that miRNAs 
play during melanogenesis. The obtained results confirm a new pivotal layer of regulation, 
wherein a single miRNA is able to modulate both mRNA and protein levels of several 
important pigmentation genes. The compelling evidence that has been gathered indicate a key 
role in melanocyte pigmentation for miR-145, and thus in the regulation of melanogenesis. 
Interestingly, melanocytes overexpressing miR-145 display a perinuclear 
accumulation/retention of melanosomes followed by a hypopigmentary phenotype. Discovery 
of this important pigmentation factor may expand the therapeutic potential of miRNAs in 
pigmentary disorders. 
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Supplementary Material 
 
Supplementary Material and Methods 
 
Luciferase reporter assay for human myosin VA 
Taking into account that the 3’ UTR of human myosin VA (NM_000259) contains three 
putative miRNA binding sites (position 129-136; seed 1, position 731-737; seed 2, position 
781-787; seed 3) for hsa-miR-145 we decided to investigate if an interaction occurs between 
hsa-miR-145 and myosin VA (MYO5A) by utilizing an in vitro luciferase assay (Lal et al., 
2009; Mestdagh et al., 2010). The 3’UTR, containing the three miRNA binding sites of 
MYO5A, was PCR amplified using cDNA derived from primary human melanocytes and the 
primers listed in Table S3. The primers are flanked by either an XhoI or a NotI restriction site 
located at their 5’ end to allow ligation into the multiple cloning region of the psiCHECK™-2 
Vector (Promega Benelux B.V., Leiden, The Netherlands) containing a downstream stop 
codon of a SV40 promoter-driven Renilla luciferase gene. This resulted in a wild-type (WT) 
3’UTR MYO5A luciferase reporter construct. In order to determine which binding site (or a 
combination) is responsible for the miR-145_MYO5A interaction, single mutants (Mut) were 
created by introducing four point mutations in the seed region of each of the three hsa-miR-
145 binding sites of MYO5A. More specific, each miRNA binding site of MYO5A was first 
mutated using the Quikchange II XL Site-directed mutagenesis kit (Agilent, Diegem, 
Belgium) according to the manufacturer’s instructions. Primers for site-directed mutagenesis 
(Table S4) were designed as described by Mavrakis et al. (2011) using the Quikchange Primer 
Design Program available on the Agilent website (www.agilent.com/genomics/qcpd) and 
taking into account the company’s recommendations. Four point mutations were introduced 
into the seed region of each putative miR-145 binding site namely at positions 1, 3, 4 and 5 as 
shown in Figure S2. Presence of the mutated nucleotides was confirmed by sequencing and 
alignment against the sequence of the WT construct and the reference sequence NM_000259. 
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Next, HEK293T cells were seeded in RPMI medium supplemented with 10% FCS (Life 
Technologies Europe B.V., Ghent, Belgium) at a density of 10 000 cells/well in an opaque 96-
well plate (Thermo Fisher Scientific, Erembodegem, Belgium). Twenty-four hours after 
seeding, cells were co-transfected with either the WT or single mutant (Mut1, Mut2 or Mut3) 
3’UTR psiCHECK-2 vector construct (100 ng) (Promega Benelux B.V., Leiden, The 
Netherlands) and 50 nM of the miR-145 mimic (Life Technologies Europe B.V., Ghent, 
Belgium) or an equal amount of the Pre-miR negative control 2 (NC) (AM17111, Life 
Technologies Europe B.V., Ghent, Belgium) using 0.4 µl DharmaFECT Duo (Thermo Fisher 
Scientific, Erembodegem, Belgium). All transfections were conducted three times in 
triplicate. Cells were lysed and luminescence was quantified 48 hours after transfection using 
the Dual-Glo Luciferase assay system (Promega Benelux B.V., Leiden, The Netherlands) on a 
FLUOstar OPTIMA microplate reader (BMG LABTECH, Isogen Lifescience, Sint-
Pietersleeuw, Belgium). Data were normalized against the activity of the Firefly luciferase 
gene. The results were reported as an average luciferase activity +/- SEM and statistically 
evaluated using an unpaired t-test.  
 
Pre-miR / anti-miR transfections and miRNA quantification 
To achieve upregulation of miR-145, chemically modified, ds nucleic acids are transfected 
with minimal cellular stress to mimic endogenous mature miRNAs (pre-miR-145, PM11480, 
Life Technologies Europe B.V., Ghent, Belgium). This enables detailed study of miRNA 
biological effects via gain-of-function experiments. Pre-miR negative control 2 (AM17111, 
Life Technologies Europe B.V., Ghent, Belgium) are random sequence pre-miR molecules 
that have been extensively tested in cell lines and tissues and validated not to produce 
identifiable effects on known miRNA function. To induce downregulation of miR-145, small, 
chemically modified ssRNA molecules, designed to specifically bind to and inhibit 
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endogenous miRNA molecules, were transfected into the cells (anti-miR inhibitor anti-145, 
AM111480, Life Technologies Europe B.V., Ghent, Belgium). This enables detailed study of 
miRNA biological effects via loss-of-function experiments. An anti-miR inhibitor negative 
control #1 (AM17010, Life Technologies Europe B.V., Ghent, Belgium) was used as a 
negative control. 
For qPCR and western blot analysis, melan-a cells were plated into P60 dishes at a density of 
500 000 per dish in RPMI medium without TPA. Twenty-four hours later the medium was 
replaced with 2.4 ml fresh medium. The final pre-miR-145 or anti-miR-145 concentration was 
50 nM after adding 18 µl HiPerFect Transfection Reagent (Qiagen, Hilden, Germany). This 
solution was mixed by vortexing and incubating for 10 minutes at room temperature to allow 
formation of transfection complexes. These complexes were added in a drop-wise manner 
onto the cells. The medium was replaced 24 hours later and gene silencing was monitored at 
the desired time points by harvesting the cells for either RNA isolation, or used to prepare 
whole-cell lysates (see below). All transfections were performed in triplicate.   
Quantification of miR-145 by TaqMan Real-Time PCR was carried out as described by the 
manufacturer (Life Technologies Europe B.V., Ghent, Belgium). Briefly, 800 ng of template 
RNA was reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit and 
the multiplex RT primer pools containing miRNA-specific stem-loop primers. A five times 
diluted (5x) RT-product was introduced into a 5 µl PCR reaction. Reactions were run in 384-
well plates on a 7900HT RT-qPCR system (Applied Biosystems Europe, Halle, Belgium) at 
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
MiR-145 expression was normalized between different samples based on the values of U6 
small nucleolar RNA expression. 
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Western blotting   
Lysates of melan-a cells were made and immunoblotting was performed as previously 
described by Van Gele et al. (2008). Primary antibodies included the purified rabbit anti-
Myosin Va exon F (1/5000)) (Van Gele et al., 2008), a rabbit polyclonal antibody against 
Rab27a (H-60) (1/200, sc-22756, Santa Cruz, Heidelberg, Germany), a polyclonal antibody 
against Fascin1 (S-18) (1/200, Santa Cruz: sc-16578), a polyclonal antibody PEP7 for the 
detection of Tyrosinase, provided by Vincent Hearing (Jimenez et al., 1991), and a mouse 
monoclonal antibody GAPDH clone B-5-1-2 (1/10000, Sigma-Aldrich, Bornem, Belgium). 
The latter was used to control loading and to perform normalisation. The blots were incubated 
with the appropriate HRP-conjugated secondary antibody (1/3000, Amersham Biosciences 
Ltd, Buckinghamshire, UK). Detection was performed with an ECL detection system kit 
(Amersham Biosciences Ltd, Buckinghamshire, UK). Quantification software (TotalLab, Life 
Science analysis essentials, TotalLab™ TL100, version 2006c nonlinear dynamics) has been 
used to quantify the loading of the different proteins after detection with an Ultima 16si 
(Isogen Life Science, Temse, Belgium).    
  
Immunohistochemistry 
To co-immunostain myosin Va and melanosomes, fixed melan-a cells were incubated 
overnight at 4°C with a polyclonal myosin Va exon F antibody (1/500) (Van Gele et al., 
2008) and the monoclonal mouse anti-human melanosome marker HMB45 (1/40, Dako, 
Heverlee, Belgium). Human primary melanocytes were incubated for 2 hours at RT with a 
mouse monoclonal NKI-beteb antibody directed against the (pre) melanosomal silver protein 
(1/40, Melanoma-associated antigen, 100kD, (Monosan, Uden, The Netherlands)), together 
with the myosin Va exon F antibody. The appropriate secondary antibodies were used: an 
Alexa 594-conjugated mouse anti-rabbit (1/1000) or an Alexa 488-conjugated rabbit anti-
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mouse (1/1000) antibody (Life Technologies Europe B.V., Ghent,, Belgium). 4’,6-diamidino-
2-phenylindole (DAPI) was added during the washing steps to detect cell nuclei. Cells were 
mounted on glass microscope slides with Glycergel (DakoCytomation, Carpinteria, CA, USA) 
and confocal images were captured with a Leica Sp5 AOBS confocal microscope (Leica, 
Mannheim, Germany). Images were taken by using a 63× HCX PL Apo 1.4 oil objective. 
DAPI was excited with a UV diode laser at 405 nm, Alexa 488 by using the 488 line of a 
Multi Argon laser and TRITC (or Alexa 594) by a HeNe laser at 543 nm. For actin labelling, 
cells were incubated with the fluorescent F-actin probe TRITC phalloidin (Sigma-Aldrich, 
Bornem, Belgium).   
 
 
Quantification of hypopigmented pellets of human primary melanocytes 
In order to follow up on any hypopigmentation effect of miR-145 on human primary 
melanocytes, harvested cell pellets were closely observed and photographed. This experiment 
was performed on four individual human primary melanocyte donors. These cells were either 
transfected with negative (pre-miR) controls, pre-miR-145 or a siRNA aimed against 
tyrosinase and were harvested 6 days post transfection. Equivalent amounts of cells were spun 
down in separate wells for each condition and quantified. Quantification was performed by 
measurement of mean intensities of various regions of interest with the use of Fiji software. 
The mean values of the two controls were rescaled to one and compared to the treated 
conditions, which finally resulted in quantification of reduced pigmentation. 
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Supplementary Tables 
 
Table S1. List of 16 differentially expressed miRNAs after ssUV and forskolin treatment 
of melan-a cells. Average down- or upregulation represents the mean (+/-SEM) of three 
independent treated melan-a cells versus non-treated cells (P-values were determined by 
unpaired t-test). 
 
 
Average 
downregulation 
+/- 
SEM 
P-value 
miR-125b 1.7297 0.0564 0.001046 
miR-139-5p 1.9895 0.0424 0.000081 
miR-145 15.7547 0.8445 0.000013 
miR-155 2.5090 0.2547 0.013583 
miR-193* 6.0061 1.3398 0.017236 
miR-206 3.3674 0.1817 0.000435 
miR-218 2.7893 0.1655 0.000983 
miR-221 2.7950 0.0381 0.000003 
miR-222 3.2741 0.0876 0.000026 
miR-28 2.3109 0.1330 0.001939 
miR-335* 2.7718 0.0536 0.000012 
miR-365 2.4574 0.1444 0.001745 
miR-455 3.4144 0.5351 0.020630 
    
 
Average 
upregulation 
+/- 
SEM 
P-value 
miR-130b 2.1078 0.1145 0.0027 
miR-182 3.0727 0.1256 0.0002 
miR-9 2.7486 0.2019 0.0028 
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Table S2. Sequences (forward (F) and reverse (R)) of 3’UTR luciferase reporter 
constructs for mouse Myo5a.  
 
Position 123-130 of Myo5a 3' UTR (NM_00259) 
 
mmu-miR-145 F (site 1) 
TCGAGAAGTACTGATTATCTCTAAAGGAAGATGTTAACTGGAAATCCACCCCTCCCCCCAGAATC
CTTTCGATGC                  miRNA binding site with 8mer seed (black) 
 
mmu-miR-145 R (site 1) 
GGCCGCATCGAAAGGATTCTGGGGGGAGGGGTGGATTTCCAGTTAACATCTTCCTTTAGAGATA
ATCAGTACTTC                                                                                             
 
Scrambled (Scr) sequence 
 
mmu-miR-145_Scr. F (site 1) 
TCGAGAAGTACTGATTATCTGATTATGCAATAAAAGATGCGAGATCCACCCCTCCCCCCAGAATC
CTTTCGATGC               scrambled miRNA binding site with 8mer seed (black)                                           
 
mmu-miR-145_Scr. R (site 1) 
GGCCGCATCGAAAGGATTCTGGGGGGAGGGGTGGATCTCGCATCTTTTATTGCATAATCAGATA
ATCAGTACTTC                                                    
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Table S3. Overview of the primers used to make the 3’UTR construct for human Myosin 
VA for the luciferase reporter assays. The primers amplify a 1.273 kb part of the 3’UTR 
region of MYO5A, containing the three miRNA binding sites. The forward primer (F) is at the 
5’ end linked to the XhoI restriction site and the reverse primer (R) is at the 5’ end linked to 
the NotI restriction site (highlighted in bold) for ligation into the multicloning site of the 
psiCHECK™-2 Vector. 
 
Gene Accession N° Primer  5’3’ Annealing 
Temp 
Product 
size 
MYO5A NM_000259 F: CTCGAGTCTTGCCCGAAATAAGAACCCA 57 °C 1273 bp 
  
R: GCGGCCGCTCTCTCTCTGTCACCCAGGC 
  
 
 
 
 
 
 
 
 
Table S4. Primers used for site-directed mutagenesis to create mutant reporter 
constructs used in the luciferase reporter assays for human myosin VA. The miRNA 
binding seed is underlined and the mutated nucleotides are highlighted in bold. 
 
Gene 
MYO5A 
Primer  5’3’ 
 
Site 1 
 
F:GTACTGATTATCTCCCAAATGAGAAGTCATTCAAGTGAAATCTCCCTAGAATACTTTCATCACTTTG  
 
R:CAAAGTGATGAAAGTATTCTAGGGAGATTTCACTTGAATGACTTCTCATTTGGGAGATAATCAGTAC 
  
Site 2 F:TTCTGTTTACAATTCAATCAGATCACAGTTTTCAAGTGATTATATGCAAATACCTACAGATTCACCTGC 
 
R:GCAGGTGAATCTGTAGGTATTTGCATATAATCACTTGAAAACTGTGATCTGATTGAATTGTAAACAGAA 
 
Site 3 F:TACAGATTCACCTGCACAAGTAGCAGACCCGTTAAAGTCATGTAGTAATATGACAAAATGC 
R:GCATTTTGTCATATTACTACATGACTTTAACGGGTCTGCTACTTGTGCAGGTGAATCTGTA 
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Supplementary Figures 
 
            
 
Figure S1. Downregulation of miR-145 induces an upregulation at the mRNA expression level of 
genes involved in the pigmentary process. 
Melan-a cells were transfected with 50 nM anti-miR-145 or with an equal amount of anti-miR 
negative control #1. Cells were harvested for RNA isolation at 24, 48, 72 and 96 hours post 
transfection (PT). The relative expression levels of miR-145 and several pigmentation genes were 
determined by RT-qPCR. The mean ratio of the treated samples versus the mean ratio of negative 
controls was plotted for miR-145 and each analyzed gene at the different time-points. MiR-145 
expression was downregulated at each time-point. A maximum increase in gene expression level (ratio 
>1) was observed at 48 hours PT for genes involved at the onset of pigmentation, except for Trp1 (a) 
and for genes involved in the transport and transfer of melanosomes to the cell periphery (Fscn1, 
Myo5a and Rab27a) (b). The ratio (treated versus control) is shown as the mean (+/-SEM) of three 
independent experiments. P-values were determined with an unpaired t-test. 
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Figure S2. Overview of the three putative miR-145 binding sites in the 3’UTR of human Myosin 
VA. The position of the seed regions is based on the NCBI Reference Sequence NM_000259. 
Predicted consequential pairing of target region and hsa-miR-145 is indicated by vertical lines. The 
nucleotides indicated in red were mutated in the mutant 3’UTR constructs.  
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Figure S3. Overexpression of miR-145 in human primary melanocytes results in downregulation 
of MYO5A and other pigmentation genes. Human primary melanocytes (MCs) were transfected with 
50 nM pre-miR-145 or with pre-miR negative control. Cells were harvested for RNA isolation at 48, 
96 and 144 hours PT. The relative expression levels of miR-145 and a set of pigmentation genes was 
determined by RT-qPCR. The mean ratio of the treated samples versus the mean ratio of negative 
controls was plotted for miR-145 and each analyzed gene at the different time-points. A clear 
overexpression of miR-145 was observed (a). A time-dependent decrease in gene expression level 
(ratio <1) was observed for genes involved at the onset of pigmentation  (b) and for genes involved in 
the transport and transfer of melanosomes to the cell periphery (c). Ratios (treated versus control) are 
the mean (+/-SEM) of qPCR duplicates of human MCs derived from MC donor 1. Data are 
representative for three independent experiments (i.e. analysis performed on MC derived from other 
donors). (d) Western blots and densiometry values showing downregulation of MYO5A protein in 
pre-miR-145 transfected MCs versus control samples (NC) in three different MC donors. 
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Figure S4. Expression of anti-miR-145 restores the perinuclear accumulation of melanosomes in 
primary human melanocytes. Human melanocytes were transfected with anti-miR negative control 
(left), siMYO5A exon F (50 nM) (middle) or co-transfected with 50 nM siMYO5A exon F and 50 nM 
anti-miR-145 (right). Cells were fixed 6 days after transfection and co-immunostained with the 
melanosomal marker NKI-beteb (green) and a rabbit polyclonal anti-Myosin Va (MYO5A) exon F 
antibody (red).  Expression of MYO5A is strongly reduced in siMYO5A transfected melanocytes and 
melanosomes (NKI-beteb) accumulate around the nucleus whereas melanosomes show a peripheral 
distribution in control-transfected cells. Co-transfection of siMYO5A and anti-miR-145 into human 
melanocytes results in co-localization of NKI-beteb and MYO5A and a redistribution of the 
melanosomes to the cell periphery and dendritic tips due to elevated expression of (endogenous) 
MYO5A. Bars = 20µm. 
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3.2 Studying the role of miR-145 in melanoma cell lines  
 
 
Introduction 
 
MiRNAs are known to influence genes in cancer that mediate processes during tumorigenesis, 
such as inflammation, cell cycle regulation, stress response, differentiation, apoptosis, and 
invasion. The observations made in the previous study strongly suggest that miR-145 is a 
major, if not the only miRNA regulator that can shut down the entire pigmentation process 
causing hypopigmentary effects in pigment forming cells (melanocytes). Transformation of 
melanocytes leads to uncontrolled growth and eventually gives rise to malignant melanoma. 
Previous studies in other cancer types demonstrated a tumor suppressor function for miR-145. 
Therefore, an investigation to uncover a potential link, which involves miR-145 in both 
melanogenesis and melanomagenesis was relevant. The functional analysis involving our 
melanoma cell lines has provided additional evidence that miR-145 indeed has an invasion 
suppressor role in malignant melanoma.  
 
 
 
 
Paper:  
 
Peter Dynoodt, Reinhart Speeckaert, Olivier De Wever, Inès Chevolet, Lieve 
Brochez, Jo Lambert and Mireille Van Gele. 
MiR-145 overexpression counteracts migration and invasion of metastatic 
melanoma cells. Int J of Onc., 7 dec 2012, doi: 10.3892/ijo.2013.1823.  (Early 
online publication) 
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CHAPTER 4 
DISCUSSION AND FUTURE PERSPECTIVES 
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4.1 Identification of miRNAs involved in pigmentation 
 
miR-145; a novel target to influence pigmentation 
 
The mechanism of formation of skin pigmentation, which is the production of melanin, is 
notably complex, and involves a multitude of consecutive steps. The pigmentation of human 
skin results from the synthesis of melanin by dendritic cells located at the basal layer of the 
skin, called melanocytes. These cells contain organelles, called melanosomes, which are 
miniature factories that synthesize melanin. Melanosomes are transported to the exterior 
regions of the cytoplasm, and migrate along the dendrites to be transferred from the 
melanocytes into keratinocytes, which are the predominant cell type in the outermost layer of  
the skin. The keratinocytes are transported to the surface of the skin during the epidermal 
differentiation process (Gilchrest et al., 1996; Hearing and Tsukamoto, 1991). 
  
Since hyperpigmentation disorders result from an overproduction of melanin, which is related 
to sun exposure, hormonal changes, prescription drugs or acne scarring, it is important to 
develop novel therapeutic approaches, the rationale of which is based on the inhibition of 
certain key genes involved during pigmentation. It therefore appears promising to develop 
novel inhibiting compounds, that are both highly effective, and exhibit good tolerance. Of 
late, the use of miRNA therapeutics enabled specific applications, not only in the cosmetic 
field, such as skin or hair care, but also in dermatological, and pharmaceutical fields. 
 
Most synthetic skin-lightening compounds are cytotoxic with respect to melanocytes, 
potentially causing permanent depigmentation of the skin. These agents are commercially 
available, and are administered to patients, often with disappointing results. Even the use of 
hydroquinone, the gold standard product for treatment of hyperpigmentation, is still subject to 
controversy, due to a bad safety profile (Draelos, 2007; Toombs, 2007). Therefore, there is a 
high need for novel therapies with a better efficiency and less side effects. 
 
MiRNAs are tiny non-coding, regulatory RNAs, involved in several fundamental cellular 
processes such as differentiation, proliferation, and apoptosis (Ambros, 2004). They exert 
their function by binding to a subset of target mRNAs, resulting in translational repression 
and/or increased degradation of mRNAs. The use of miRNAs makes it possible to obtain a 
specific inhibition of the synthesis of a target protein by degradation of the mRNA encoding 
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the protein. The degradation of the target mRNA is obtained through activation of the RISC 
complex (RNA Induced Silencing Complex), which acts through the binding of the anti-sense 
strand of the dsRNA to the mRNA (Sun et al., 2010). 
 
Manipulation of miRNA functions, either by mimicking or inhibiting them, is emerging as a 
highly promising therapeutic strategy. Such developments can contribute to our understanding 
of melanogenesis and melanoma progression and reveal new targets for selective therapy. 
Compared to the single-target knock down achieved by siRNA, the miRNA solution simply 
utilizes naturally occurring components that are inherent to the melanocyte machinery. 
Depending on the sequence complementary to their targeted gene transcripts, miRNAs can 
induce either mRNA degradation or suppression of protein synthesis, or both, while siRNAs 
primarily trigger mRNA degradation. As a result, the effect of miRNAs is generally broader, 
moderate, specific, and less adverse than siRNAs. Moreover, intrinsic drawbacks of siRNA-
induced gene silencing (including off-target effects, elicitation of the interferon response, and 
interference with the endogenous miRNA biosynthesis) are eliminated when using miRNAs, 
due to their specific biogenesis and mechanism of action (Judge et al., 2005; Sledz et al., 
2003). 
 
The specific objective of this work was to investigate and identify miRNAs involved in the 
tanning process. Several reports revealed that the expression levels of miRNAs may change in 
response to different stress factors such as hypoxia  and UV treatment (Kulshreshtha et al., 
2007; Pothof et al., 2009). In order to investigate this in vitro, an experimental pigmentation 
model was developed, in which we utilized a UV radiation source and addition of a 
melanogenic stimulator, forskolin, to monitor melanogenesis. Treated mouse melanocytes 
(melan-a) were irradiated with a solar simulator (UVB+UVA), while untreated cells were 
used as controls. Using a RT-qPCR based miRNA expression profiling technology, we 
identified a miRNA signature containing 16 miRNAs, separating differentially expressed 
miRNAs in treated melan-a cells versus untreated cells. In total, 13 miRNAs were found to be 
downregulated, while only 3 were upregulated. This suggests that the role of miRNAs in 
melanogenesis is associated with a widespread miRNA repression, rather than an activation. 
Closer inspection of the 16 differentially expressed miRNAs showed a remarkable expression 
level of miR-145, which was 15 times downregulated in treated mouse melanocyte cells 
(melan-a), compared to non-treated controls. Subsequently, functional studies involving the 
overexpression of this specific miRNA show that a negative moderation of key genes taking 
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part in melanogenesis, is feasible. This was also confirmed at the protein level. 
Overexpressing miR-145 in melan-a cells additionally causes the redistribution of 
melanosomes from the peripheral to the perinuclear region. When transfections of miR-145 
mimics are performed in human primary melanocytes, a clear accumulation/retention of 
melanosomes around the nucleus is observed. A hypopigmentary effect of harvested cell 
pellets distinguishes miR-145 transfected melanocytes from non-transfected counterparts. 
 
We presume miRNA-145 attacks the melanogenesis pathway along two fronts (Figure 1). 
One is located at the forefront of melanogenesis, attacking the SOX9 gene, partially 
responsible for the initiation of melanogenesis. The other front is situated towards the end of 
the melanogenesis pathway, including the correct transfer of the melanosomes from the 
melanocytic dendrites into the keratinocytes. These genes located at the periphery of the 
melanocytes, are MYO5A, RAB27A, and FSCN1. We propose a working model for miR-145, 
in which these two fronts cooperate, pulling all the remaining melanogenesis genes (MITF, 
TYR and TRP1,) downwards, leading to a hypopigmentary phenotype.  
 
 
Figure 1: miR-145 mechanism of action       
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With regard to the experiments using antagomiRs, an increase of the same genes influenced 
by the miRNA “mimics” was observed. This was only temporally, and gene expression levels 
returned to basal levels 72 hours after transfections. Knockdown of miR-145 is insufficient to 
switch on the melanogenesis process in vitro. In order to switch “ON” these important 
processes, subsequent key regulators probably also need to be switched on to further proceed 
along the melanogenesis pathway. We hypothesize that it is easier to shut down certain 
processes, than to enable a complex pathway, which involves a multitude of consecutive steps 
to run smoothly. 
 
Parallel with this miRNA signature, it would be interesting to integrate mRNA signatures 
which could broaden the overall understanding of how these players interact. We were able to 
determine that miR-145 can downregulate Sox9, Mitf, Tyr, Trp1, Myo5a, Rab27a, and Fscn1. 
As such, we only determined a subset of genes that are directly or indirectly regulated by this 
specific miRNA. To obtain a comprehensive understanding of the genes that are influenced 
by miR-145, a genome wide expression analysis to dissect and analyze the genes that are 
involved in, or controlled by, the transcriptional regulatory function of this specific miRNA is 
essential. This could also be a way of establishing what kind of side effects to expect when 
utilizing miR-145 for potential further treatments.   
 
With regard to the miRNA signature containing 16 differentially expressed miRNAs, we 
opted for the study of a single miRNA most likely to have the largest biological effect. The 
choice for miR-145 was obvious. The role that other miRNAs play during the pigmentation 
process still needs to be clarified. Synergistic or antagonistic effects must be taken into 
consideration when multiple miRNAs cooperate to repress a gene or pathway. Overexpressing 
one of these miRNAs might not produce any measurable effect, leading to the false 
conclusion that this miRNA is not involved in the pigmentary process.  
 
Topical application of miRNAs into the skin is one of the last and major hurdles that need to 
be taken in order to accomplish a miRNA-based treatment against skin disorders. The barrier 
of the stratum corneum needs to be breached in order to enable nucleic acids to reach the 
melanocytes located at the basal layer of the skin. A non-viral lipid-based carrier for 
cutaneous gene therapy has been optimized and characterized in our lab. This liposomal 
formulation, termed SECosomes is highly efficient, not only in cultured skin cells, but also in 
excised human skin explants (Geusens et al., 2009). An ex vivo 3D pigmented human 
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reconstructed skin model, suitable for functional testing of RNAi-induced depigmentation is 
available, and investigations into translating a miRNA-based depigmentation agent into a 
proof-of-principle are warranted (Van Gele et al., 2011). One previous study reported the 
development and use of a specific miRNA (miR-434-5p) product, able to reduce pigmentation 
successfully in  vitro as well as in vivo, without any detectable cytotoxic effects (Wu et al., 
2008). This illustrates the feasibility of the use of miRNA-mediated skin lightening agents. 
Additionally, skin pigmentation models are regarded as excellent tools to study the 
efficiency/potential of newly developed “small RNA” delivery vehicles, and can be combined 
with any other easy to follow miRNA expression. Eventually, these delivery vehicles can then 
be combined with other miRNA mimics/antagomirs, leading to novel miRNA-mediated 
topical therapies to treat skin disorders such as psoriasis, atopic dermatitis and melanoma. 
Applied research introducing miRNAs to the clinical realm is not only a big challenge for 
therapeutic companies, but also for academic researchers and dermatologists (Baker, 2010). 
 
It is recommended to view the potential ethical implications that are associated with 
developing pigment-altering therapeutics and the bioethical debates that have sparked up 
through these endeavors. Certainly in the context of recent discoveries relating to genes 
associated with the pigmentation process, which could suggest opportunities into creating 
effective skin-lightening products. Various societies consider the urge to use skin whitening 
products, roots from a racism perspective, while other societies regard this as reaching out to 
a definition of beauty or attractiveness.  Considering another undertone where the degree of 
some ones skin tone can be associated to unequal distributions of income, job opportunities, 
and education, consequently leading to prejudiced social, cultural, and economic positions in 
society, seems highly unfair (Dadzie and Petit, 2009). In line with this it has even been 
confirmed that skin tone can directly affect health outcomes through differences in the quality 
of health care services provided to some racial minorities and indirectly through the 
aforementioned inequalities (Daniels, 2009; Hersch, 2008).  
Isn’t it is the obligation of society to provide treatments and enhancements for the purpose of 
meeting general needs and removing barriers that restrict equal opportunities, thus promoting 
the equality of opportunity? Well, by developing an appearance-altering skin-lightening 
therapeutic, one could eventually have a positive impact on the health of its recipients seen in 
the light of race and health issues. On the other hand, skin-lightening technology is 
controversial and could further undermine racial differences and public support for 
cooperative healthcare systems due to racial and financial reasons. Justice systems should 
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overlook the values that affect opportunity as well as prioritizing what the healthcare needs. 
Justice may even be required to restrict access to race-related enhancements if it creates even 
more differences by unfairly distribution. These restrictions should be coordinated at an 
international level, which encompasses all countries once certain products have been 
considered dangerous for health. This should be done to avoid over-the-counter sales of skin-
lightening products in certain countries while they are banned in others, due to health 
concerns (e.g.; hydroquinone). It is also important to fore come potential health risks by 
educating the public that it is important to be safe than sorry when using these products. In 
line with these statements it seems highly relevant that the right centers are set up with the 
right specialists who can inform the public what the right choices are after the appropriate 
research has been performed. These bioethical challenges are by no means restricted to skin-
lightening technologies but can also be applied to a broad scope of enhancement technologies 
that are currently growing. 
 
4.2 Unraveling the role of miR-145 in melanoma 
 
miR-145 overexpression counteracts migration and invasion of metastatic melanoma cells 
 
Several factors such as heritable predisposition and genetic mutations increase the risk to 
melanoma. Ultraviolet radiation such as that emitted by the sun is directly absorbed by DNA, 
which causes genetic mutation, and is a major risk factor for all types of skin cancers 
including malignant melanoma. Genetic mutations in melanocytes are associated with 
histological changes along a continuum that may accommodate an invasive malignancy. 
MiRNAs are known to be aberrantly expressed in many cancer types, and can either exert 
tumor suppressive or oncogenic functions. Loss-of-function or gain-of-function of tumor 
suppressor miRs or oncomiRs, respectively could influence the progression of melanoma. 
Manipulation of these molecules as potential targets for cancer therapies has generated great 
interest. They can also serve as diagnostic markers to predict patient prognosis and outcome. 
General therapeutic strategies in relation to antisense-mediated inhibition of oncogenic 
miRNAs, and miRNA replacements with miRNA mimics or viral vector-encoded miRNAs, 
are currently under investigation (Trang et al., 2008). 
 
By overexpressing miR-145 in melanoma cell lines with different metastatic potential, and 
performing several functional studies we aimed to investigate the tumor suppressor role of 
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miR-145. Three melanoma cell lines were examined in gain-of-function experiments 
involving miR-145. The results from these experiments show that by overexpressing miR-145 
the metastatic potential and progression of malignant melanoma cells can be decreased 
thereby demonstrating an invasion suppressor function of this miRNA. Combined with an 
appropriate (topical) delivery system this miRNA is potentially a useful target in the therapy 
of melanoma. To uncover the mechanism on how miR-145 accomplishes its invasion 
suppressor role we examined the expression levels of target genes FSCN1, MYO5A, SOX9 
and of one indirect target (RAB27A) after overexpression of miR-145. Neither SOX9, MYO5A 
nor RAB27A were involved in the biological effects caused by miR-145 mimics.  
In several previous cancer studies knockdown of FSCN1 by miR-145 has demonstrated its 
contribution to oncogenesis and progression of these cancer types (Chiyomaru et al., 2010; 
Fuse et al., 2011). We therefore focused on the role of FSCN1 and its interaction with miR-
145 in melanoma. In contrast to these previous studies, where the knockdown of FSCN1 leads 
to a reduced cell migration, we observed an increase in cell invasiveness, and thus an increase 
in metastatic potential in two of our cell lines, namely, BLM and WM793. We hereby 
hypothesize that FSCN1 exerts a different role in melanoma compared to other tumor types 
and that other target genes of miR-145 that do not take part in the FSCN1 pathway such as 
MUC1, MMP-11, FLI1 and JAM-A could be involved in cell migration and invasion (Gotte et 
al., 2010; Sachdeva and Mo, 2010; Zhang et al., 2010). In breast cancer cell lines it has been 
suggested that miR-145 leads to suppression of invasion, and metastasis by directly targeting 
MUC1, which in turn causes the downregulation of β-catenin, cyclin D1, and cadherin 11 
(Sachdeva and Mo, 2010). While in another study the inhibition of breast cancer cell 
invasiveness is attributed to the direct targeting of miR-145 towards JAM-A, a membrane 
protein involved in cell-cell adhesion and cell motility regulation, and to the knockdown of 
the actin-bundling protein fascin (Gotte et al., 2010). Further in depth studies, by using 
microarray analysis for example between miR-145 transfected and control melanoma cells 
which could eventually lead to identification of invasion targets of miR-145, will be necessary 
to uncover the precise mechanism on how miR-145 performs its invasion suppressor role in 
melanoma. 
 
 
The transition of a normal melanocyte to metastatic melanoma may involve several 
histological intermediates including an atypical/dysplastic nevus of varying stages of severity, 
or melanoma in situ and invasive melanoma. Indeed, melanoma diagnosed and treated during 
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the radial growth phase have been shown to have an excellent prognosis. Currently, there is 
no cure for late stage melanoma. As a result, early detection plays a critical role in reducing 
melanoma morbidity and mortality. MiR-145 may be a potential prognostic marker to predict 
if melanoma may become metastatic. New prognostic tools to complement the visual 
examination of lesions, especially early-stage melanoma and borderline lesions, and those that 
lack the classic appearance of melanoma could significantly enhance the detection process, 
thereby increasing survival rates of patients.  
 
 
General Conclusion 
We were able to identify miR-145 as a key player during melanogenesis. Attention should be 
paid to potential side effects, and more research is needed on the possible invasion suppressor 
role that miR-145 might possess in melanoma.  
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5.1 Summary 
Melanogenesis is a complex process that takes place when melanocytes are activated by UVR 
emitted by the sun, followed by the generation of melanin. In a response, melanocytes protect 
the skin against the harmful effects of UVR by producing melanin-containing melanosomes, 
and by transferring them to the neighbouring keratinocytes where the melanin pigment serves 
as a shield against UV damage. Like most of these processes, distinct signaling pathways, 
which result in the activation of specific transcription factors, and a whole range of 
subsequent reprogramming of gene expression, will help the melanocyte to overcome the 
harmful UV effects. How these processes are delegated and controlled has not yet been 
completely elucidated. MiRNAs have recently been shown to be regulators of gene 
expression, and are known to be involved during stress induced responses; but until to date, 
no miRNAs have been associated with UV stress resulting in the augmentation of ultraviolet-
induced pigmentation. It would therefore be interesting to find a link between melanogenesis 
and miRNA gene regulation, adding a new layer of control during pigmentation. Additionally, 
this can open new paths towards the discovery and development of innovative therapies for 
the treatment of patients with skin pigmentation disorders. 
The primary aim of this thesis is to determine which miRNAs are involved during the 
pigmentation process, and to analyze their biological function in melanocytes. We 
investigated the effects of solar simulated UV (ssUV), and forskolin, on pigmentation in 
mouse melanocytes (melan-a), following an experimental model, involving several 
consecutive treatments. These treatments stimulate the processing and transport of 
melanosomes, which play an essential role during pigmentation. Melanocytes that did not 
receive these treatments were used as controls. Next, total RNA, containing all miRNAs, was 
isolated from these melanocytes. To determine the expression levels of these miRNAs, a high-
throughput and sensitive miRNA expression profiling platform was subsequently applied to 
measure the miRNA expression levels of melanocytes treated with ssUV and forskolin versus 
untreated melanocytes. By comparing the miRNA profiles of treated melanocytes versus 
control melanocytes, we were able to profile 540 miRNAs. Based on these data, a miRNA 
signature (consisting of 16 miRNAs) associated with ssUV and forskolin treatments was 
established for the first time. Among the miRNAs that were differentially regulated one 
specific miRNA showed a marked knockdown in the treated melanocytes: miR-145 displayed 
a 15-fold downregulation. Functional studies were performed wherein we assessed whether 
the absence or overexpression of this miR-145 altered cell function (phenotypical effect). 
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Overexpression studies (gain-of-function) of miR-145, in mouse and human melanocytes, 
showed that several important pigmentation genes were influenced by this miRNA, both at 
the gene and protein expression level. One of them was the motor protein myosin VA 
(MYO5A) involved in intracellular melanosome transport in melanocytes through the 
formation of a RAB27A-MLPH-MYO5A tripartite complex. By use of a luciferase reporter 
assay we were able to demonstrate direct targeting of MYO5A by miR-145 in mouse and 
human melanocytes. In addition, gain-of-function studies clearly demonstrated a biological 
response in primary human melanocytes cultured in vitro, whereby the melanocytes obtained 
a hypopigmentary effect in a time dependent manner, as a result of perinuclear 
accumulation/retention of melanosomes. In conclusion, our results reveal that miR-145 is a 
key regulator of the pigmentary process. Consequently, miR-145 could possibly become a 
potential target in the treatment of skin pigmentation disorders. 
In the second part of the thesis we studied the role of miR-145 in melanoma cell lines. 
Previous studies have already mentioned miR-145 as a tumor suppressor in other tumor types. 
Due to the fact that melanoma is generated from malignant melanocytes, and that miR-145 
plays such a prominent role during the pigmentation process, we decided to investigate the 
effects of miR-145 in several melanoma cell lines, and to examine if the same tumor 
suppressor functions could be observed in melanoma. Several functional studies involving 
wound healing assays, proliferation assays, and matrix cell invasion assays, were performed 
after overexpressing miR-145 in the melanoma cell lines. These gain-of-function experiments 
in invasive melanoma cell lines resulted in a suppression of cell migration and invasive 
potential, while an anti-proliferative effect was observed in a primary, non-invasive 
melanoma cell line. In previous studies, involving other tumor types, it was shown that miR-
145 exerts its tumor suppressor role via FSCN1, but surprisingly when knocking down 
FSCN1 in our melanoma cell lines, this did not inhibit cell proliferation and migration. On the 
contrary, FSCN1 knockdown increased cell invasion leading us to suggest that miR-145 does 
not necessarily act via targeting FSCN1. Further studies will be needed to clarify the 
mechanism of action that miR-145 has as a tumor suppressor. The overall results from these 
experiments show that by overexpressing miR-145, a decrease in cell migration, and invasive 
potential of malignant melanoma is observed, showing a reduced invasion suppressor function 
of this miRNA.   
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5.2 Samenvatting 
Melanogenese is een complex proces dat plaatsvindt wanneer melanocyten worden 
geactiveerd door UV radiatie (UVR) van de zon, met als gevolg de productie van melanine.  
Als reactie op UVR, beschermen melanocyten de huid tegen de schadelijke effecten van UVR 
door het produceren van melanine bevattende melanosomen, en door hen over te brengen naar 
aangrenzende keratocyten, waar het melanine pigment dient als schild tegen UV schade. 
Zoals bij de meeste van deze processen worden de melanocyten bij het overwinnen van de 
schadelijke UV effecten geholpen door verschillende signaleringsroutes die de activatie van 
specifieke transcriptiefactoren tot gevolg hebben, en door een hele reeks van daaropvolgende 
herprogrammaties van genexpressie, Hoe deze processen worden gedelegeerd en 
gecontroleerd is nog niet volledig duidelijk. Recent werd aangetoond dat miRNAs regulatoren 
zijn van genexpressie, en wij weten dat zij betrokken zijn bij stress geïnduceerde respons, 
maar tot op heden werden geen miRNAs geassocieerd met UV stress, of met een toename van 
ultraviolet-geïnduceerde pigmentatie. Het zou daarom interessant zijn een verband te vinden 
tussen melanogenese en miRNA genregulatie, om aldus een nieuw controleniveau aan het 
pigmentatieproces toe te voegen. Dit kan tevens perspectieven bieden voor de ontdekking en 
ontwikkeling van innovatieve therapieën voor de behandeling van patiënten met 
huidpigmentatie aandoeningen. 
 
Het hoofddoel van deze thesis was het bepalen van welke miRNAs betrokken zijn bij het 
pigmentatieproces, en het analyseren van hun biologische functie bij melanocyten. Wij 
onderzochten de effecten van gesimuleerde zon UV (ssUV), en forskoline, op pigmentatie in 
muis melanocyten (melan-a), volgens een experimenteel model met verschillende 
opeenvolgende behandelingen. De behandelingen stimuleren de productie en het transport  
van melanosomen, die een essentiële rol spelen tijdens pigmentatie. Melanocyten die geen 
behandeling hadden ondergaan werden gebruikt als controle. Vervolgens werd totaal RNA, 
dat alle miRNAs omvat, geïsoleerd uit deze melanocyten. Om het expressieniveau van deze 
miRNAs te bepalen, werd een hoge doorvoer en een gevoelige miRNA expressie profilering 
platform toegepast, ten einde de miRNA expressieniveaus van met ssUV en forskoline 
behandelde, versus niet behandelde melanocyten te meten. Door het vergelijken van miRNA 
profielen van behandelde versus controle melanocyten, konden 540 miRNAs worden 
geprofileerd. Steunend op deze gegevens werd voor de eerste keer een miRNA signatuur 
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(bestaande uit 16 miRNAs) geassocieerd met ssUV en forskoline behandelingen opgesteld. 
Eén van de onder de in behandelde melanocyten differentieel gereguleerde miRNAs, 
vertoonde een uitgesproken knockdown effect: miRNA-145 was 15-voudig neergereguleerd. 
Functionele studies werden uitgevoerd waarbij we inschatten of de afwezigheid of 
overexpressie van dit miR-145 de celfunctie wijzigt (fenotypisch effect). 
Overexpressiestudies (gain-of-function) van miR-145, in melanocyten afkomstig van zowel 
muis als mens, toonden aan dat verschillende belangrijke pigmentatiegenen werden beïnvloed 
door dit miRNA, zowel op gen- als proteïne expressieniveau. Eén van deze was het 
motorproteïne myosine VA (MYO5A), betrokken bij intracellulair melanosoomtransport, via 
de vorming van een RAB27A-MLPH-MYO5A driedelig complex. Door middel van een 
luciferase reporter test konden we directe targeting van MYO5A door miR-145, in 
melanocyten afkomstig van zowel muis als mens, aantonen. Tevens demonstreerden gain-of-
function studies een duidelijke biologische respons in vitro, in primaire humane melanocyten, 
waarbij de melanocyten een tijdsafhankelijk hypopigmentair effect verwierven, ten gevolge 
van accumulatie/retentie van melanosomen. Uiteindelijk tonen onze resultaten aan dat miR-
145 een centrale regulator is van het pigmentatieproces. Bijgevolg kan miR-145 mogelijks 
een beloftevol doelwit worden in de behandeling van huidpigmentatie aandoeningen. 
 
In het tweede deel van deze thesis bestudeerden we de rol van miR-145 in melanoom 
cellijnen. Vroegere studies vermeldden reeds miR-145 als een tumor suppressor in andere 
tumortypes. Doordat melanoom ontstaat vanuit kwaadaardige melanocyten, en door het feit 
dat miR-145 een dermate belangrijke rol speelt tijdens het pigmentatieproces, werd besloten 
de effecten van miR-145 op verschillende melanoom cellijnen te onderzoeken, ten einde vast 
te stellen of dezelfde tumor suppressor functies konden worden vastgesteld in melanoom. 
Verschillende functionele studies, waaronder wondheling- en proliferatietesten, en matrix cel 
invasietesten, werden uitgevoerd na overexpressie van miR-145 in de melanoom cellijnen. 
Deze gain-of-function experimenten in invasieve melanoom cellijnen resulteerden in 
suppressie van celmigratie en invasief potentieel, terwijl een anti-proliferatief effect werd 
waargenomen in een primaire, non-invasieve melanoom cellijn. In vroegere studies met 
andere tumortypes, werd aangetoond dat miR-145 zijn tumor suppressor rol vervult via 
FSCN1, maar bij een knockdown van FSCN1 in melanoom cellijnen, konden wij nochtans 
geen inhibitie van celproliferatie en migratie vaststellen. Daarentegen verhoogde FSCN1 
knockdown celinvasie, hetgeen er ons toe aanzet te suggereren dat miR-145 niet noodzakelijk 
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via FSCN1 targeting werkt. Verdere studies zullen nodig zijn om het mechanisme van miR-
145 als tumor suppressor te ontrafelen. In het algemeen tonen deze resultaten aan dat door 
overexpressie van miR-145, een afname in celmigratie, en invasief potentieel van 
kwaadaardig melanoom kan worden vastgesteld, duidend op een verminderde invasie 
suppressor functie van dit miRNA.  
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5.3 Résumé 
La mélanogenèse est un mécanisme complex qui se déroule quand les mélanocytes sont 
activées part le UVR émis par le soleil, suivi par la génération de mélanine. Dans une 
réaction, les mélanocytes protègent la peau contre l’impact nuisible des UVR, en produisant 
des mélanosomes contenants de la mélanine, et en les transférants aux kératocytes 
envoisinantes, où le pigment mélanine sert de bouclier contre les dégâts causés par l’UV. 
Comme la plupart de ces mécanismes, des sentiers de transmission particuliers, qui résultent 
dans l’activation de facteurs de transcription et tout une gamme de reprogrammation 
d’expression de gènes ultérieures, aideront le mélanocyte à vaincre les effets nuisibles de 
l’UV. La manière dont ces mécanismes sont délégués et contrôlés, n’a pas encore été 
entièrement élucidé. Les MiRNA ont récemment été reconnus comme des régulateurs 
d’expression de gènes, et sont connus comme impliqués dans des processus provoqués par le 
stress, mais jusqu’ aujourd’hui, aucun miRNA n’a été associé avec le stress causé par l’UV, 
résultant dans une augmentation de pigmentation provoquée par l’ultra-violet. Ainsi il serait 
intéressant de trouver un lien entre la mélanogenèse et la régulation des gènes par le miRNA, 
ajoutant une nouvelle couche de contrôle pendant la pigmentation. En plus, ceci pourrait 
ouvrir de nouveaux sentiers dans la découverte et le développement de thérapies innovatives 
pour le traitement de personnes affectées par des troubles de pigmentation de la peau. 
 
Le but prinipal de cette thèse est de déterminer quels miRNA sont impliqués dans le processus 
de pigmentation, et d’analyser leur fonction biologique dans les mélanocytes. Nous avons 
étudiés les effets d’UV solaire simulé (ssUV), et de forskoline sur la pigmentation dans des 
mélanocytes de souris (melan-a), suivant un modèle expérimental, impliquant différents 
traitements consécutives. Ces traitements stimulent le développement et le transport des 
mélanosomes qui jouent un rôle essentiel pendant la pigmentation. Des mélanocytes sans 
traitement étaient utilisés comme contrôle. Ensuite, la totalité d’ RNA, contenant tous les 
miRNA, était isolée de ces mélanocytes. Pour déterminer les niveaux d’expression de ces 
miRNA, un plate-forme profilé à haut débit et sensifif à l’expression du miRNA était appliqué 
pour mesurer les niveaux d’expression du miRNA des mélanocytes traités avec ssUV et 
forskoline, versus des mélanocytes non traités. En comparant les profiles des mélanocyrtes 
traités versus les mélanocytes de controle, nous étions capables de profiler environ 540 
miRNA. Basé sur ces données, une signature miRNA (comportant 16 miRNA) associée avec 
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les traitements ssUV et forskoline, était établie pour la première fois. Parmis les miRNA 
régulés différentiellement, un miRNA spécifique montrait un knock-down prononcé dans les 
mélanocytes traités: miR-145 étalait une régulation de 15 fois à la baisse. Des études 
fonctionnelles étaient effectuées pour évaluer si l’absence ou la surexpression de ce miR-145 
changait la fonction cellulaire (effet phénotypique). Des études de surexpression (gain 
d’expression) du miR-145, dans des mélanocytes de souris et humains, démontraient que 
plusieurs gènes de pigmentation importantes étaient influenencées  par cet miRNA, autant sur 
le niveau d’expression génétique que sur le niveau des protéines. Parmis ces derniers se 
trouvait la protéine moteur myosine VA (MYO5A), impliquée dans le transport intracellulaire 
des mélanosomes par la formation d’un complexe tripartite RAB27A-MLPH-MYO5A. En 
utilisant un essai reporter luciferase, nous étions capables de montrer un ciblage direct du 
MYO5A par le miR-145 dans des mélanocytes de souris et humains. En plus, des études de 
gain de fonction démontraient clairement une réponse biologique dans des mélanocytes 
primaires humains, cultivés in vitro, par lequel les mélanocytes obtenaient un effet 
hypopigmentaire en fonction du temps, à la suite d’accumulation/rétention périnucléaire des 
mélanosomes. En conclusion, nos résultats démontrent que le miR-145 est un régulateur clé 
du processus de pigmentation. Par conséquent, le miR-145 pourrait se montrer un cible 
potentiel dans le traitement de troubles de pigmentation de la peau.  
 
Nous avons étudié le rôle de miR-145 dans des lignées cellulaires de mélanomes dans la 
deuxième partie de la thèse. Des études antérieures ont déjà mentionné miR-145 comme un 
suppresseur de tumeurs dans d’autres types de tumeurs. Par le fait que le mélanome est généré 
à partir de mélanocytes malignes, et que miR-145 joue un rôle tellement important dans le 
processus de pigmentation, nous avons choisi d’examiner les effets de miR-145 dans plusieurs 
lignées cellulaires de mélanomes, et d’examiner si les mêmes fonctions de suppression de 
tumeurs puissent être observés dans des mélanomes. Plusiers études fonctionnelles impliquant 
des essais de cicatrisation de plaies, des essais de prolifération, et des essais d’invasion de 
cellules matrices, étaient effectuées après avoir surexprimé miR-145 dans les lignées 
cellulaires de mélanomes. Ces essais de gain de fonction dans des lignées cellulaire de 
mélanomes envahissantes, résultaient dans une suppression de migration cellulaire et de 
potentiel envahissant, tandis qu’un effet anti-prolifératif était observé dans une lignée 
cellulaire primaire, non-envahissante de mélanomes. Dans des études antérieures, impliquant 
d’autres types de tumeurs, il était établie que miR-145 déploie son rôle de suppresseur de 
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tumeurs par FSCN1, mais surprenant, en knocking down FSCN1 dans les lignées cellulaires 
de mélanomes, ceci n’inhibait pas la prolifération cellulaire et la migration. Au contraire, 
FSCN1 knockdown augmentait l’invasion cellulaire, nous menant à suggérer que miR-145 
n’agit pas nécessairement par le ciblage du FSCN1. Des études ultérieures seront nécessaires 
pour clarifier le mécanisme d’action du miR-145 comme suppresseur de tumeurs. Le résultat 
global de ces essais montre qu’en surexprimant miR-145, une réduction de migration 
cellulaire et du potentiel envahissant de mélanome maligne étaient observé, démontrant une 
fonction de suppression envahissante réduite du miRNA. 
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